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ABSTRACT OF DISSERTATION 
 
 
REGULATION OF PLATELET EXOCTOSIS AND ITS ROLE IN DISEASES 
 In addition to their role in hemostasis, platelets appear to contribute to vascular 
inflammatory diseases. Platelets achieve this through the secretion of various pro-
thrombotic and pro-inflammatory molecules.  Platelet secretion is mediated by integral 
membrane proteins called Soluble NSF Attachment protein REceptors (SNAREs).  
SNAREs come from both granule/vesicle membranes (v-SNAREs) and target membranes 
(t-SNAREs) to form a trans-bilayer complex that promotes membrane fusion and 
subsequent granule cargo release.  The work described in this dissertation dissects 
various, yet related aspects of platelet secretion in both physiological relevant and 
pathological circumstances.  
Atherosclerosis is a leading cause of death in the westernized countries and a 
major contributor to heart attacks and strokes. Given the potential involvement of 
platelets in atherosclerosis and previous work from our laboratory showing that VAMP-8 
is the primary v-SNARE for platelet secretion, one part of this dissertation focuses on the 
role of VAMP-8- mediated secretion in atherosclerosis. The data showed that the deletion 
of VAMP-8 in the ApoE-/- null model of chronic atherosclerosis attenuated plaque 
development compared to the wild type littermates. Aged (50 week) VAMP-8-/-/ApoE-/- 
mice showed a reduction in lesion size compared to ApoE-/- controls, as measured by Oil 
Red-O staining of the plaques in the aortic sinus and by en face analysis of plaques in the 
aortic arch. These data show that the loss of VAMP-8 attenuates the development of 
atherosclerotic plaques and suggest that platelet secretion contributes to atherosclerosis. 
Considering the vital role of platelet secretion in both physiological and 
pathological conditions, it is essential to understand how it is regulated.  SNARE proteins 
are controlled by a range of regulatory molecules that affect where, when, and with 
whom they form trans-bilayer complexes for membrane fusion.  One family of such 
regulators is the Munc18 family: platelets contain three (Munc18a-c).  The second part of 
this dissertation focuses on the role of Munc18b/STXBP2. Mutations in the 
Munc18b/STXBP2 gene underlie Familial Hemophagocytic Lymphohistocytosis type 5 
(FHL5), which is a life- threatening disease caused by dysregulation of the immune 
system. Platelets from two biallelic FHL5 patients had almost undetectable levels of 
Munc18b/STXBP2 levels; the levels of Munc18a increased slightly and Munc18c levels 
were unaffected.  Syntaxin 11 levels were affected but the levels of other secretory 
machinery proteins were normal. Platelet secretion from dense and alpha granule in two
biallelic patients and the one heterozygous patient was decreased. The release of 
serotonin from dense granules, and platelet factor 4 (PF4) from alpha granules was 
profoundly affected in the biallelic patients and partially affected in the heterozygote 
heterozygous patient. Lysosome release was affected only from the platelets of the 
biallelic patients. These data indicate that Munc18b plays a key role in platelet secretion.  
Ras is the prototypical member of a family of low molecular weight, GTP-binding 
proteins.  It affects various cellular functions by cycling between an active, guanine 
triphosphate (GTP) and an inactive guanine diphosphate (GDP) -bound state. Little is 
known about the role of Ras activation in platelets. The third part of this dissertation 
focuses on what could be learned about Ras’ role by analyzing platelets from patients 
with Noonan Syndrome.  Specific mutations in the genes encoding elements of Ras 
signaling pathways are associated with Noonan Syndrome. Platelets from Noonan 
Syndrome patients with a mutation in kRas (F156V) were analyzed and shown to have a 
defect in aggregation in response to low levels of agonist.  These data suggest that Ras 
may play a functionally relevant role in platelet activation. 
In summary, the experiments presented in investigations of this dissertation 
support a role for platelet secretion in several pathological conditions and suggest that 
platelet secretion assays may serve as useful as diagnostic tools for some genetic 
diseases. In addition, these studies elucidate the importance of understanding the 
regulation of platelet exocytosis, to drive the development of new antithrombotic 
therapeutics. 
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Chapter One 
Introduction 
 
Thesis Overview 
In this thesis research, various yet related aspects of platelet secretion have been 
discussed. Platelets are small, discoid, cellular fragments that circulate in the blood 
stream. Circulating platelets play a key role both in hemostasis and thrombosis. Platelets 
respond to variety of events in the body by secreting numbers of molecules from their 
granules. Upon vascular injury under physiological conditions, platelets adhere to 
subendothelial collagen, become activated, and undergo cytoskeletal rearrangements that 
allow them to aggregate and secret their granule content to form a clot. This activation of 
platelets can be pathological: inappropriate thrombosis can lead to heart disease or stroke 
(Ruggeri 2002). The secretion of platelet granule content is a complex and important 
process that can influence several physiological and pathological conditions, e.g. wound 
healing, inflammation, coagulation and malignancy.  These effects raise several questions 
that are central to this dissertation, how the platelet secretion machinery is regulated and 
how can platelet secretion influence physiological and pathological processes.  
 
Platelet Biology and Structure 
Wright described the production of platelets from the bone marrow in the 20th 
century as “detachment of plate-like fragments or segments from pseudopods” of the 
megakaryocytes (Wright 1910). The maturation of megakaryocytes and the production of 
platelets are controlled by several cytokines such as thrombopoietin and potentially 
interleukin (IL)-3, IL-6, and IL-11 (Kaushansky 1995; Kaushansky et al. 2002). 
Megakaryocytes undergo endomitotic divisions and become polyploid with at least 16N 
of DNA content (Ebbe 1976; Hata et al. 1993). Once the process of nuclear division is 
completed, the cytoplasm continues to mature and the cell mass increases (Paulus 1970). 
At this stage, the cytoplasm of a megakaryocyte will develop a demarcation membrane 
system (DMS), a dense tubular system (DTS) (Daimon et al. 1982), and granules (Ebbe 
1976).  In megakaryocytes, the DMS serves as a reserve for proplatelet formation and 
membrane extension. In mature platelets, the DMS develops into the open canalicular 
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system (OCS) (Radley et al. 1982). DTS is the site of prostaglandin synthesis in platelets, 
and doesn’t stain with surface membrane tracers such as ruthinum red. The process of 
granule biogenesis starts during the development of megakaryocytes. There are three 
types of secretory granules: α-granules, dense granules, and lysosomes.  
The most abundant granules are the α-granules. Platelets comprise 50-80% of α-
granules. They vary in size between 200 and 500 nm in diameter (Frojmovic et al. 1982). 
Electron microscopy was used to determine the morphology of α-granules as a spherical 
shape with a dark central nucleus (Harrison et al. 1993). Proteomic studies suggest that 
α-granules contain and release hundreds of different types of molecules (Maguire et al. 
2003; Coppinger et al. 2004). This diversity makes the platelet a potentially 
multifunctional cell whose functions range from normal hemostasis and wound healing to 
pathologies such as inflammation. Proteins synthesized by megakaryocytes (Kieffer et al. 
1987) and endocytosed proteins from the plasma (Handagama et al. 1987; Behnke 1992) 
are present in α-granules. For platelet adhesion, α-granules contain adhesive molecules, 
such as fibrinogen (Broekman et al. 1975), thrombospondin (Jaffe et al. 1982), von 
Willebrand factor (vWF) (Slot et al. 1978), fibronectin (Zucker et al. 1979). Proteins that 
are involved in the coagulation pathway such as factor V and factor IX and plasmingoen 
activator inhibitor-1 (PAI-1; (Booth et al. 1988; Rendu et al. 2001; Smyth et al. 2009) are 
also present in α-granules. P-Selectin and αIIbβ3, which are important for platelet 
aggregation, are integral membrane proteins that are present in granule membranes and 
become exteriorized upon activation (Cramer et al. 1990). Inflammatory cytokines, such 
as RANTES and platelet factor 4 (PF4) (McLaren et al. 1982) and angiogenic (VEGF, 
PDGF, bFGF) (Nurden et al. 2008) and anti-angiogenic (CXCL4) proteins are also 
present in α-granules (Brill et al. 2004).  
Human platelets contain three to eight dense granules per platelet (Holmsen et al. 
1979). By electron microscopy, dense granules, as their name indicates, are electron 
dense in whole mounts and appear black after osmium staining (Gunay-Aygun et al. 
2004). They are the smallest platelet granules, around 200-300 nm in diameter. Dense 
granules are formed in early stages of megakaryocyte development and filled with their 
contents during maturation. Small molecules such as calcium (Holmsen and Weiss 1979), 
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serotonin (5-HT) (Da Prada et al. 1979), phosphate, adenosine diphosphate (ADP), and 
adenosine triphosphate (ATP) (Wurzinger 1990) are stored in dense granules. These 
molecules play a key role in platelet activation. For instance, serotonin release leads to 
vasoconstriction and enhancement of platelet release (Watts 2002; Walther et al. 2003), 
while ADP is important for recruiting and activating neighboring platelets and thus 
enhances the thrombus formation. The release of content from dense granules is the most 
rapid of the three granule release events. 
Lysosome is the third class of granules in platelets, and is intermediate in size 
between α-granules and dense granules, and around 175–250 nm in diameter. Lysosomes 
have been identified in the earliest form of recognizable megakaryocytes. Lysosomes 
contain many hydrolytic enzymes including β–hexosaminidase, acid hydrolases, 
glycosidase, heparinase, and cathepsin. These enzymes play an important role in 
degradation of proteins and lipids, thus might play a role in platelet remodeling (Ciferri et 
al. 2000). The membrane of the lysosome contains the lysosomal integral membrane 
protein LIMP (CD63) and the lysosomal-associated membrane proteins, LAMP-1 and 
LAMP-2 (Metzelaar et al. 1992). These integral membrane proteins are heavily 
glycosylated at the luminal side of the lysosome, forming a protective coat from the 
lysosomal granule hydrolytic enzymes (Rendu and Brohard-Bohn 2001). Activated 
platelets express the lysosomal specific membrane proteins on their surface, which can be 
used as a marker for detecting platelet function. A summary of the major platelet granule 
content is presented in (Table 1-1).  
 
Platelet Activation  
The primary physiological role of platelet in sensing the damaged vascular 
endothelium and its accumulation at site of injury to initiate blood clotting was identified 
in 1865 (Bizzozero 1865). There are several agonists identified to bind their 
corresponding receptors on the platelet surface, and initiate several signaling cascades 
that lead to platelet activation. The initiation of platelet adhesion to the damaged vessel 
wall requires platelets to adhere to exposed collagen, which is one of the primary platelet 
agonist that is exposed on the vascular lesion and binds to GPVI receptor on platelet 
surface causing platelet adhesion to the vascular damaged area. Von Willebrand’s factor 
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(vWF) is expressed on the endothelium and subendothelium matrix and binds to GPIb 
receptor on platelets to enhance platelet adhesion. The adhesion of platelets leads to 
initiation of signaling events that leads to cytoskeleton changes, and secretion of more 
than 300 proteins (Rendu and Brohard-Bohn 2001) that causes platelet aggregation. 
Secreted agonists by activated platelets, such as ADP, thromboxane A2, and 
thrombin lead to further activation and aggregation of platelets. Once bound to their 
corresponding G protein coupled receptor, these agonists (Table 1-2) activate 
phospholipase C (PLCβ), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PI-4, 
5-P2) to diacylglycerol (DAG) and inositol tri phosphate (IP3) that causes Ca2+ channels 
in the endoplasmic reticulum to open (Lawrence et al. 2010). The increase in intracellular 
calcium activates protein kinase c (PKC) and PI3K, which cause activation of 
cytoskeletal proteins such as talin (Petrich et al. 2007) and initiate inside-out signaling in 
platelets. Activated talin can then bind to the cytoplasmic domain of the β3 subunit 
causing a conformational change that leads to the dissociation of the cytoplasmic and 
transmembrane domains of αIIb and β3, which in turn causes the oligomerization of 
integrin. This conformational change in this receptor leads to its binding to fibrinogen 
and thus promoting platelet-platelet interaction and aggregation.  
The binding of several agonists to their corresponding platelet receptors is very 
important for platelet function in hemostasis. Defects in platelet receptors can lead to 
bleeding disorders that involve αIIbβ3 integrin receptor (Glanzmanns thrombasthenia) 
and GPIb receptor (Bernard-Soulier syndrome; (Nurden et al. 2008). 
 
SNARE Proteins (t-SNARE and v-SNARE)   
Soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) 
proteins were characterized in 1980’s and 1990’s (Block et al. 1988; Trimble et al. 1988; 
Sudhof 1989; Bennett et al. 1992; Sollner et al. 1993) as key components of protein 
complexes that mediate all intracellular membrane fusion.  Membrane fusion is an 
essential process that is required for membrane biogenesis, intracellular trafficking, and 
cellular exocytosis, including hormone and enzyme secretion, and neurotransmission. 
The importance of divalent cations, especially Ca2+, in membrane fusion was studied in 
the 1970’s by D. Papahadjopoulos et al (Newton et al. 1978), throughout the 1980’s by 
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different groups including S. Ohki (Ohki 1982). In the 1990’s, James E. Rothman and his 
research group demonstrated that SNAREs proteins are involved in membrane fusion in 
mammalian cells (Sollner, Whiteheart et al. 1993; Whiteheart et al. 1993; Weber et al. 
1998). There are two classes of SNARE proteins: target membrane proteins (t-SNAREs) 
on the plasma membrane, and the secretory vesicle-associated membrane proteins 
(VAMPs or v-SNAREs) on the vesicle membrane. The interaction of the t-SNAREs; two 
SNAP-25 and a syntaxin on the plasma membrane, with the v-SNARE; VAMP on the 
vesicle membrane, leads to the formation of a four-helix bundle that spans the two 
bilayers and mediate the membrane fusion. The assemblies of the SNARE complexes that 
bridge the two membranes are called trans-SNARE complexes, and it is the minimum 
component required for membrane fusion (Weber, Zemelman et al. 1998). The 
completion of the membrane fusion is called cis complexes, which is a conformation 
where all the SNAREs are associated with the same membrane (Ungar et al. 2003).  
The v-SNAREs, such as VAMPs, are type II integral membrane proteins, with a 
single transmembrane domain (TMD) that is required to anchor SNAREs to the 
membrane. The t-SNAREs can be divided to two types: the SNAP23/25 type (SNAP-23, 
SNAP-25, SNAP-29, sec9p) and the syntaxin type (syntaxin-1 to -19, etc.). The SNAP-
23/25 like SNARE proteins have two SNARE motifs and no TMD, but they are anchored 
to the membrane through a thioester-linked acyl group (Ungermann et al. 2005). Syntaxin 
is a type II integral membrane protein that consists of a SNARE motif and an N-terminal 
regulatory domain (Dietrich et al. 2003). In SNARE proteins, the SNARE motif is 
approximately 60–70 residues in length (Weimbs et al. 1997; Jahn et al. 1999) and is 
adjacent to the C-terminal TMD. Monomeric SNARE motifs are disordered, and their 
interactions lead to the formation of parallel four-helix bundles. This structure of the 
assembled SNARE motifs is stabilized by the presence of heptad repeats of the 
hydrophobic residues on the same side of the α-helix (Poirier et al. 1998; Sutton et al. 
1998; Antonin et al. 2002). This parallel arrangement of SNARE motifs brings both the 
transmembrane anchors and the two membranes into close proximity to form the cis-
SNARE complex and mediate fusion (Hanson et al. 1997). Finally, after fusion occurs, in 
order for SNAREs proteins to be reused for more fusion processes, the cis-SNARE 
complex needs to be disassembled. The process of cis-SNARE complex disassembly is 
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mediated by the chaperone NSF (N-ethylmaleimide-sensitive factor) and the co-
chaperone SNAP and uses the energy of ATP hydrolysis (Fasshauer et al. 1997; 
Fasshauer et al. 2002). The interaction of NSF (hexamer) and three α-SNAPs with the 
cis-SNARE complex lead to the formation of a transient 20 S complex (Hohl et al. 1998). 
The ATP hydrolysis by NSF leads to the disassembly of the 20 S complex along with the 
cis-SNARE complex.  This allows SNARE proteins to be in the trans-complex assembly 
and the SNARE proteins to be recycled for more membrane fusion events (May et al. 
2001) (Figure 1-1). 
 
 SNAREs in Platelet Secretion 
 The presence of SNARE proteins in human platelets was first identified by 
Whiteheart et al (Lemons et al. 1997). There are 17 isoforms of syntaxins in human 
genome. In platelets the (t-SNAREs) syntaxin-2, -4, -7, and 11 were detected (Lemons, 
Chen et al. 1997; Flaumenhaft et al. 1999; Chen et al. 2000; Chen et al. 2000). Syntaxin-2 
and -4 were found to be important for platelet secretion. Syntaxin-2’s role in platelet 
secretion was determined by using a polyclonal syntaxin-2 inhibitory antibody in 
permeabilized human platelets. The secretion from the three granules (α-granules, dense 
granules, and lysosome) was inhibited. A monoclonal syntaxin-4 inhibitory antibody had 
an effect on secretion from α–granules and lysosomes only. A syntaxin-7 antibody had no 
effect on platelet secretion from permeabilized human platelets. Recently the role of 
syntaxin-11 in human platelets was defined by our group (Ye et al. 2012 submitted). The 
genetic mutations of the syntaxin-11 gene are associated with the rare autosomal 
recessive disorder called Familial Hemophagocytic Lymphohistocytosis type 4 (FHL 4). 
The disease is characterized by a defect in degranulation from cytotoxic T cells and 
Natural Killer (NK) cells that leads to hyperactivation of the immune system. The 
manifestations of the disease include hepatosplenomegaly and cytopenias. Variable 
bleeding diatheses have been reported in these patients. The disease is fatal unless bone 
marrow transplantation is performed at an early age. Both SNAP-25 and SNAP-23 were 
identified in platelets. SNAP-23 is known to play a function in platelet secretion. Using 
anti-SNAP-23 Fab fragment and the SNAP-23 C-terminal peptide, secretion from all 
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three platelet granules were inhibited (Flaumenhaft, Croce et al. 1999; Reed et al. 1999; 
Chen, Bernstein et al. 2000; Chen, Lemons et al. 2000; Polgar et al. 2003).   
In human genome, there are 9 VAMPs (VAMP-1-8, excluding VAMP-6, sec22, 
ND YKT6P) (Bock et al. 2001). The v-SNAREs that are present in human and murine 
platelets include: synaptobrevin/VAMP-2, cellubrevin/VAMP-3, TI-VAMP/VAMP-7, 
and endobrevin/VAMP-8 (Polgar et al. 2002; Schraw et al. 2003; Ren et al. 2007). In this 
section, I will focus more on the v-SNARE VAMP-8, since it is part of this thesis project.  
The role of VAMP-2 and VAMP-3 in platelet secretion was contraversial. In vitro 
experiments using the tetanus toxin endopeptidase showed that P-Selectin exposure was 
inhibited (Flaumenhaft, Croce et al. 1999). This toxin not only cleaves VAMP-3, but it 
also cleaves VAMP-2, which was not detected at that time. So it was concluded that 
VAMP-3 was important for platelet secretion from α-granules. This work was followed 
by another experiment using the cytoplasmic domain of VAMP-2, -3, and -8 as inhibitors 
(Polgar, Chung et al. 2002). VAMP-3 was reported to be important for the secretion from 
both α-granules and dense granules. In vivo studies with VAMP-3-/- mice showed that 
VAMP-3 was not required for platelet secretion (Schraw, Rutledge et al. 2003). During 
that time, VAMP-2 was identified in both human and murine platelets. VAMP-2 is 
important for neurotransmitter release and insulin release from pancreatic cells 
(Randhawa et al. 2000). Tetanus toxin insensitive VAMP (TI-VAMP)/VAMP-7 has been 
idetified to play a role in epithelial cells (Galli et al. 1998). The N-terminal region of 
VAMP-7 is called the longin-domain, that has been shown to be important in membrane 
trafficking and SNARE complex formation (Advani et al. 1999).  
The endobrevin/VAMP-8 was first identified as the v-SNARE that mediates 
fusion between early and late endosomes (Wong et al. 1998; Antonin et al. 2000), by 
forming a complex with syntaxin-7, -8, and vti1b. Another role of VAMP-8 was reported 
in mast cell degranulation. VAMP-8 forms a complex with syntaxin-4 and SNAP-23, 
which plays a role in the regulated secretion of mast cells (Sander et al. 2008). VAMP-8 
was found to be a major player in exocytosis in pancreatic acinar cells (Wang et al. 
2004). Using VAMP-8-/- mice, secretion from the zymogen granules from the pancreatic 
cells was reduced compared to the wild type.  In VAMP8–/– mice, the secretion of 
granzyme A and granzyme B was significantly compromised in cytotoxic T lymphocytes 
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(Loo et al. 2009). The role of VAMP-8 in platelet secretion was well studied by several 
groups (Polgar, Chung et al. 2002; Ren, Barber et al. 2007). Our group showed that 
VAMP-8 is required for platelet secretion from the three granules. Thrombin-stimulated 
platelets from VAMP-8-/- mice had a significant defect in secretion compared to wild type 
controls. Further work showed that VAMP-8 is the major v-SNARE responsible for 
platelet secretion in human and mouse. Although the secretion defect is significant, it is 
not complete; there is a residual secretion. When high levels of thrombin (0.5 U/mL) 
were added, the secretion defect in platelets was over-ridden. The residual secretion was 
sensitive to tetanus toxin in VAMP-8-/- platelets suggesting that VAMP-2 and/or VAMP-
3 might play a secondary role in platelet secretion. The role of VAMP-8 in hemostasis 
was demonstrated using the in vivo laser induced-injury model (Graham et al. 2009). 
These results show that VAMP-8-/- mice are defective in thrombus initiation and growth, 
but thrombus formation was not ablated, suggesting that the secondary VAMPs mediate 
enough secretion for reduced clot formation. Since the VAMP-8-/- mice exhibited an in 
vivo hemostatic phenotype consistent with their ex vivo platelet secretion defect, it 
appeared that VAMP-8-/- mice can be used as a model to study the importance of platelet 
exocytosis in atherosclerosis. 
 
Platelet Pathophysiology 
Atherosclerosis and Platelet Secretion 
Atherosclerosis is a chronic inflammatory disorder (Ross 1995), characterized by 
intimal wall thickening of medium and large arteries (Stary et al. 1995). One theory 
explaining the development of atherosclerosis is the “Response to Injury” model that 
Russell Ross proposed over twenty years ago (Ross 1995). In brief, the process of 
atherosclerosis starts with vascular endothelium injury that leads to accumulation of 
lipids, in particular low-density lipoprotein (LDL), in the intimal area promoting 
formation of fatty streaks. As a consequence, many cells are recruited to the lesion site, 
such as monocytes, which transform into macrophages that engulf the lipid particles and 
become foam cells (Ross 1999). Platelets are also stimulated, and adhere to endothelial 
cells. As a result of these events, plaques or “lesions” develop. Rupture of the plaque and 
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the subsequent occlusive thrombus is responsible for most acute coronary diseases and 
strokes (Viles-Gonzalez et al. 2004). 
One of the major cell types involved in atherosclerosis is the endothelial cell. 
Once activated, they express a number of surface receptor molecules, e.g. intercellular 
adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), and P- and E-
Selectins, which promote adhesion of leukocytes and platelets to the lesion area (Lamon 
et al. 2008). The deficiency of E-Selectins (the endothelial selectin) and P-Selectins (on 
endothelial cells and platelets) show an 80% and 40% protection in the early and 
advanced stages of atherosclerosis, respectively (Dong et al. 1998). 
The role of macrophage in atherosclerosis has been well documented. The 
presence of macrophages in the intima of the aorta leads to an6 influx of inflammatory 
molecules such as interleukin-1 beta (IL-1β) and tumor necrosis factor-α (TNF-α), which 
promote the inflammatory response in the area (Popa et al. 2007). Macrophage chemo-
attractant protein-1 (MCP-1) recruits macrophages to the endothelium (Egashira 2003) 
and its deletion is protective against atherosclerosis (Boring et al. 1998; Ni et al. 2001). In 
addition, macrophages can exacerbate the lesion area by secreting several growth factors 
such as transforming growth factor-β (TGF-β) that leads to smooth muscle cell 
proliferation (Tiwari et al. 2008) and metalloproteinases such as matrix 
metalloproteinase-9 (MMP-9) that degrade the extracellular matrix (ECM) proteins and 
cause plaque instability. Plaque rupture activates platelets and coagulation factors which 
ultimately lead to occlusive thrombus formation (Fuster et al. 1990).  
The involvement of platelets in the process of atherosclerosis has been suggested 
by several studies (Burger et al. 2003; Huo et al. 2003; Huo et al. 2004; Gawaz et al. 
2005). Nevertheless, the precise contribution of platelets to this process has been 
controversial and unclear. While some groups propose that platelets are involved in only 
the late stages of plaque rupture and thrombus formation, others suggest that platelets 
play a key role not only in thrombus formation in the end stage of atherosclerosis 
(Dobroski et al. 1996; Bouchard et al. 2001; Cazenave et al. 2003) but also in the 
initiation of atherosclerotic lesions (Massberg et al. 2002; Theilmeier et al. 2002; 
Chandler et al. 1961; Schonbeck et al. 2000; Langer et al. 2006). Massberg et al. showed 
that in the ApoE-/- mice, inhibition of the platelet receptor GPIbα affects platelet adhesion 
10 
 
 
to vascular endothelium before the development of the lesions, while inhibition of αIIbβ3 
had only partial effect on platelet adhesion (Massberg, Brand et al. 2002). Huo et al. 
(Huo, Schober et al. 2003)demonstrated that activated circulating platelets exacerbate 
atherosclerosis in ApoE-/- mice.  
Currently there is more focus in the literature on platelets as inflammatory cells. 
Once activated, platelets adhere and interact with endothelial cells, which leads to further 
activation of platelets and expression of cell surface adhesion molecules and chemokines 
that are important for recruitment of leukocytes. Once recruited, leukocytes such as 
monocytes bind and adhere to the vessel wall and migrate into the endothelial cells, and 
differentiate into macrophages that are critical for the formation of lesions. Thus it is 
important to understand the importance of platelet exocytosis and its effect on the 
inflammatory reaction in atherosclerosis. 
It has been documented in the literature that platelets serve as a pro-inflammatory 
mediator, through the secretion of several chemokines from their α-granules, such as PF4 
(also known as CXCL4) which is a specific platelet molecule, and RANTES (CCL5) 
promoting monocytes recruitment to the lesion and thus intensifying the inflammation in 
atherosclerosis (Huo, Schober et al. 2003). Furthermore, Pitsilos et al. (Pitsilos et al. 
2003) demonstrated that PF4 is detected in atherosclerotic human plaque, which 
demonstrates that platelets secrete their cargo at the site of the lesion. Furthermore, 
Sachais et al. (Sachais et al. 2007) showed that PF4 promotes atherosclerotic lesion 
development in mice and its deletion had a protective effect. 
In addition to the chemokines mentioned above, certain cytokines are released 
from activated platelets that lead to recruitment of leukocytes into the lesion. The 
expression of IL-1β was elevated in the arteries of ApoE-/- mice (Merhi-Soussi et al. 
2005). Activated platelets induce the secretion of the endothelial cell chemokine MCP-1 
(important for monocyte recruitment), and it was dependent on IL-1β (Gawaz et al. 
2000). Activated platelets, secrete IL-1β, which in turn increases the expression of the 
endothelial adhesion molecules, such as ICAM-1 (Gawaz, Langer et al. 2005). Although 
the exact function of IL-1β in platelets is not yet known, its release from the platelets was 
shown to have an effect on inflammation in atherosclerosis (Toma et al. 2012). 
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Additionally, platelet α-granules secrete P-Selectin, which is an adhesion 
molecule that is expressed on activated platelets and mediates the rolling of monocytes 
(Dong et al. 2000; Rendu and Brohard-Bohn 2001). This interaction can lead to the 
transmigration of monocytes into the intima of the artery (Ramos et al. 1999) and thus 
facilitate atherosclerotic lesion formation. Burger et al. (Burger and Wagner 2003) have 
shown that platelet P-Selectin enhances lesion development in ApoE-/- mice, though the 
role of endothelial cell P-Selectin was deemed more important.  
The importance of platelet glycoproteins in atherosclerosis has been documented. 
Shulz et al. showed that in ApoE-/- mice, the prolonged administration of soluble GPVI 
reduced the athero-progression, and in humans, GPVI binding to the plaque core region 
facilitates platelet adhesion and aggregation, though GPVI binding is not the only factor 
that activates the plaque formation (Schulz et al. 2008). Despite the fact that Glanzman 
thrombasthenia patients (Shpilberg et al. 2002), lacking αIIbβ3, are not protected from 
atherosclerosis, in ApoE-/- mice exposed to a wire injury to induce endothelial 
denudation, the deletion of the α-subunit of the αIIbβ3 attenuated atherosclerosis, by 
preventing platelet adhesion to the damaged endothelial cells (Massberg et al. 2005). In 
addition, recent data suggest that individuals with the single nucleotide polymorphism 
(SNP), Leu33Pro of the αIIbβ3 have higher risk of atherosclerotic plaque rupture, due to 
increased platelet activation determined by high level of platelet P-Selectin (Kucharska-
Newton et al. 2011).  
Summary: 
 Platelet secretion is mediated by SNARE proteins; the interaction between the t-
SNARE on plasma membrane and the v-SNARE on vesicle membrane lead to the 
formation of a four-helix bundle that spans the two bilayers and mediate the membrane 
fusion. Among the v-SNAREs in platelets, our group has shown that VAMP-8 is the 
primary v-SNARE required for platelet secretion from all platelet granule content. 
Platelet secretion is not only important for hemostasis but also plays a role in 
inflammatory diseases such as atherosclerosis. Thus in Chapter Three of this thesis, the 
role of VAMP-8 mediated secretion in atherosclerosis will be deciphered.  
 
Regulatory Proteins in Platelet Secretion:  
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SM (Sec1/Munc18) Proteins 
The process of exocytosis through SNARE proteins is strictly regulated. One of 
the key regulators is the Sec1/Munc18 (SM) family proteins (Sudhof et al. 2009). The 
SM proteins are highly conserved through their ~600 amino acids (60-70 KDa) (Misura 
et al. 2000). SM proteins were first identified by screening the yeast S. Ceriviseae 
secretion mutations (sec) (Novick et al. 1979), and the uncoordinated mutants of C. 
elegance (unc) (Brenner 1974). The mammalian unc18 homolog is called Munc18. There 
are seven of mammalian SM gene family members that have been identified:  Munc18a, 
Munc18b, Munc18c, Sly1, Vps45, Vps33a and Vps33b (Bock, Matern et al. 2001). 
Munc18 protein’s function is involved in intracellular trafficking and regulation of 
exocytosis (Munc18a, b, and c) (Toonen et al. 2003). Munc18 proteins act as chaperones 
specific for syntaxin/t-SNARE but they also may play a role in matching v- and t-
SNAREs to form fusogenic trans-bilayer complexes. Munc18a (also called Munc18-1, 
nSec1) is primarily expressed in neurons (Hata, Slaughter et al. 1993; Garcia et al. 1994; 
Pevsner et al. 1994); Munc18b (also called Munc18-2) is ubiquitously expressed except 
in the brain; and Munc18c (also called Munc18-3) is also ubiquitously expressed (Hata et 
al. 1995; Tellam et al. 1995; Riento et al. 1996). Munc18a was first identified to bind 
syntaxin-1 in rat brain (Hata, Slaughter et al. 1993). Both Munc18a and b can bind to 
syntaxin-1, -2, and -3, while Munc18c binds to syntaxin-2 and -4 (Hata and Sudhof 1995; 
Tellam, McIntosh et al. 1995; Tellam et al. 1997). 
There are several proposed modes for Munc18a/syntaxin-1 binding. The first 
mode is called the closed confirmation, in which binding of Munc18a causes the H3 
domain of syntaxin-1 to fold back on to the N-terminal Habc domain (SNARE binding 
motif), blocking it from binding to SNAP-25 and its cognate v-SNARE (Pevsner et al. 
1994; Misura, Scheller et al. 2000). Data indicate a negative role of Munc18a on SNARE 
complex formation, by preventing any premature SNARE complex reassembly and 
suggest that this binding interaction is important for stabilization of both Munc18a and 
syntaxin-1 in vivo (Verhage et al. 2000; Gerber et al. 2008). The second mode of binding 
to syntaxin -1 is when it is dissociated from Munc18a in which the H3 domain of 
syntaxin-1 is open and exposed to bind v-SNARE, and this is called the open 
conformation (Misura, Scheller et al. 2000; Yang et al. 2000). Recently a distinct 
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mechanism of the direct interaction between SM and SNARE proteins was suggested. 
The SM protein can bind to a specific N-terminal peptide sequence in the syntaxin, and 
this is the third mode (Yamaguchi et al. 2002).  
Munc18a plays an important role in neurotransmission; the deletion of Munc18a 
in mice causes a complete loss of neurotransmitter secretion from the synaptic vesicles, 
but the brain morphology is normal (Verhage, Maia et al. 2000). The level of syntaxin-1 
protein was significantly reduced in Munc18a deficient mice, suggesting that it is a 
chaperone for syntaxin-1. Additional data confirmed the interaction between Munc18a 
and its cognate syntaxin-1. In brain lysate the immunoprecipitated Munc18a 
coprecipitated with high amount of syntaxin-1 and vice versa (de Vries et al. 2000).  In 
addition Munc18a was shown to be an important element of large dense-core vesicle 
(LDCV) release in adrenal chromaffin cells, and its deficiency causes a 10-fold decrease 
in LDCVs (Voets et al. 2001). Munc18b interacts with syntaxin-3 and thus plays a role in 
controlling membrane trafficking at the apical plasma membrane of epithelial cells. In 
addition, cell fractionation studies demonstrated that the majority of Munc18b is 
associated with the membrane (Riento, Jantti et al. 1996). Munc18b was shown to play a 
role in the regulation of granule exocytosis by mast cells (Martin-Verdeaux et al. 2003). 
As mentioned earlier, Munc18c can interact with both syntaxin-2, and -4. The interaction 
between Munc18c and syntaxin-4 plays a vital role in insulin exocytosis in adipose tissue 
and muscle cells, in addition to its important role in endothelial cell activation (Tamori et 
al. 1998; Thurmond et al. 2000; Macaulay et al. 2002).  
Three SM isoforms are present in platelets: Munc18a, Munc18b, and Munc18c 
(Reed, Houng et al. 1999; Houng et al. 2003; Schraw et al. 2003). Using an inhibitory 
peptide (Pep3) or anti-Munc18 antibodies, our group showed that at least one isoform is 
important for platelet secretion. In permeabilized platelets, the Munc18c/Pep3 peptide 
inhibits platelet secretion from the three granules, while using Munc18a/Pep3 peptide and 
Munc18a/b polyclonal antibody inhibits platelet secretion from α–granules only. Using a 
monoclonal anti-Munc18c antibody and a peptide-based inhibitor that disrupted 
Munc18c-syntaxin-4 interactions, Reed et al. showed that Munc18c-syntaxin-4 
interactions contribute to platelet secretion and that PKC phosphorylates Munc18c after 
stimulation with thrombin (Houng, Polgar et al. 2003). Despite these insights, it is not 
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clear which of the three identified SM protein(s) is/are needed for platelet exocytosis. 
Recent studies of patients with Familial Hemophagocytic Lymphohistocytosis (FHL) 
suggest that Munc18b is important for platelet function (Sandrock et al. 2010).  
 
Familial Hemophagocytic Lymphocytosis (FHL) 
FHL was first described in 1952 as a rare, invariably fatal, autosomal recessive 
immune dysfunctional disorder of childhood, named ‘Familial Hemophagocytic 
Reticulosis’(Farquhar et al. 1952). FHL is a life threatening genetic disease resulting 
from cytotoxic T lymphocyte (CTL) and natural killer (NK) cell dysfunction. These cell 
types contain secretory lysosomes that contain perforin (form pores for granzymes to 
enter the target cell) and granzymes (the serine proteases enzymes) that are exocytosed to 
destroy the target cell. It manifests as fever, splenomegaly, with an increase of 
lymphocytes count. Five defective loci are associated with FHL; the four genes identified 
are: FHL2-perforin, FHL3-Munc13-4/Unc13D, FHL4-syntaxin-11, and FHL5-unc18b 
(Filipovich 2011). A similar genetic disease, Gricelli’s Syndrome, is caused by a defect in 
the Rab27a gene (Menasche et al. 2000). The proteins encoded by these genes are either 
cargo in cytolytic granules (perforin) or elements of the secretory machinery required for 
lytic granule exocytosis (Munc13-4, Rab27a, syntaxin-11, and Munc18b). 
Our work demonstrated that Munc13-4 is a limiting factor for platelet granule 
secretion (Ren et al. 2010). Rab27a and b have been shown to be important for platelet 
secretion (Novak et al. 2002; Tolmachova et al. 2007). These data suggest that platelets 
employ similar secretory machinery, as do CTL and NK cells. 
Summary: 
Platelet exocytosis is a highly regulated process that involves several proteins. 
Among those regulatory proteins is the Munc18 family. The roles of Munc18a and 
Munc18c have been suggested in the literature; however the role of Munc18b in platelet 
secretion needs to be further investigated. Chapter Four of this thesis will discuss the 
approach of using platelets from patients with Familial Hemophagocytic Lymphocytosis 
disorder that have a genetic defect in Munc18b gene to understand the role of Munc18b 
in platelet secretion.  
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Small GTPases in Platelets 
Small GTPases are monomeric guanine nucleotide binding proteins related to the 
α subunit of heterotrimeric G proteins, with molecular weights of 21 to 30 kD. Small 
GTPases belong to Ras superfamily (Parada et al. 1982). The small GTPase superfamily 
is divided into five major families: Ras, Rho, Rab, Arf, and Ran (Colicelli 2004; 
Wennerberg et al. 2005). Small GTPases are monomers that function as molecular 
switches in intracellular signaling. They are present in two forms:  GTP-bound (active 
form) or GDP-bound (inactive form). In response to upstream signaling, the GDP form is 
exchanged for GTP and this reaction is catalyzed by guanine nucleotide exchange factors 
(GEFs). The activated GTPases then can interact with one or more effector proteins that 
lead to activation of downstream signaling pathways. The GTPase activating proteins 
(GAPs) revert the conformation to the inactive GDP-bound form by stimulating GTP 
hydrolysis (Bernards et al. 2004). 
In platelets, there are members of Ras family (Ras, Ral, and Rap), Rho family 
(Rho, Rac, and Cdc42), and Rab family (Rab 1, 3, 4, 6, 8, 11, 27, 31, 32) (Karniguian et 
al. 1993); (Richards-Smith et al. 1999; Wilson et al. 2000). Not all of these have defined 
functions in platelets. For instance, Rho family GTPases have been shown to play roles in 
cytoskeletal remodeling and integrin activation in platelets which is important for platelet 
adhesion, aggregation, and clot retraction (McCarty et al. 2005); (Akbar et al. 2007) 
(Varga-Szabo et al. 2008). For Arf Family GTPases, our group showed that Arf6 is 
present in platelets, and it plays a role in platelet activation (Choi et al. 2006). The focus 
in this thesis will be on the Ras family GTPase, Ras protein.  
 
Ras Family GTPase 
Ras: Ras was discovered as an oncogene that is constitutively active in its GTP 
bound form. In mammalian cells, there are three ras genes encoding four Ras isoforms 
(H-Ras, K-Ras4A, K-Ras4B and N-Ras). Ras proteins are mostly located on the inner 
leaflet of the plasma membrane and function as molecular switches. In Ras, the GDP 
exchange to GTP is mediated by the GEF protein SOS. The proline rich domain of SOS 
binds to the SH3 domain of the effector protein, GRB2. The SH2 domain of GRB2 binds 
the phosphorylated tyrosine residues on tyrosine kinase receptors and that leads to the 
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localization of SOS-GRB2 complex to the plasma membrane and activation of Ras 
(Buday et al. 1993; Rozakis-Adcock et al. 1993). Activated Ras interacts with several 
effector proteins, such as: RAF, GAPp120, MEKK1 and activates the downstream 
signaling cascades of the Ras/MAPK pathway. Binding of Ras-GTP to the threonine 
kinase Raf leads to the activation of the kinases MEK, which activates ERK (Figure 1-2). 
Activation of ERK regulates transcription factors that lead to cell differentiation, 
proliferation and survival cells (Omerovic et al. 2008) (Omerovic et al. 2009). Mutations 
in Ras were detected in variety of cancer cell lines (Colicelli 2004).  
In platelets at least one isoform of Ras, the H-Ras, is present; but the presence of 
K- and N-Ras is not excluded, since anti-pan Ras immunoglobulin, which does not 
exclude various isoforms of Ras, was used (Shock et al. 1997). Ras was identified in 
platelets by immunoprecipitation followed by western blotting. Immuno-fluorescence 
microscopy was used to further confirm the presence of Ras in platelets. Kinases, 
downstream Ras, such as Raf-1, MEK (MAPK/ERK kinase), and ERK (Tulasne et al. 
2002) are all detected in platelets. Upon stimulation of human platelets with the G 
protein-coupled receptor agonist’s thromboxane A2, and thrombin, Ras was rapidly 
activated. Previous work showed that collagen and thrombin induce MEK and ERK 
activation (Borsch-Haubold et al. 1995). Watson et al showed that RAS is activated in 
platelets in response to thrombin and glycoprotein VI (GPVI) agonists (Tulasne, Bori et 
al. 2002). 
The role of ERK activation in platelet function was examined using ERK specific 
inhibitors (U0126), and platelet aggregation (Oury et al. 2002) and secretion (Toth-
Zsamboki et al. 2003) were affected. Li Z et al, showed that agonist activated platelets 
activate MAPK p38 and ERK pathways leading to platelet integrin αIIbβ3 activation (Li 
et al. 2006). In addition, the ERK pathway was found to play a role in the activation of 
store-mediated Ca2+ entry (SMCE) in human platelets (Rosado et al. 2001). Depletion of 
the intracellular Ca2+ stores triggered the Ca2+ independent activation of the ERK kinase 
pathway, leading to the activation of SMCE, independent of PI3, or 4-kinases but 
sensitive to Ras inhibitors. These data suggest that ERK is a downstream effector of Ras 
proteins in human platelets. ERK was shown to play a role in thromboxane (TxA2) 
generation (Garcia et al. 2007), and it can be affected by inhibiting ERK, though the 
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effects on aggregation are controversial (McNicol et al. 2003). Therefore, future work has 
to focus on the exact function and mechanism of action of Ras-dependent signaling 
during platelet activation. 
Ral: Present in nucleated cells, Ral GTPases, are members of the Ras subfamily, 
and consist of RalA and RalB.  Upon binding to their effector proteins, Ral GTPase 
proteins exert a variety of functions such as, exocytosis through recruiting a multi-subunit 
complex termed as “exocyst complex” that are important for targeting secretory vesicles 
to specific plasma membrane domains (Bodemann et al. 2008). Ral GTPases are also 
involved in cytoskeletal organization through filamin (Feig 2003). In platelets, both RalA 
and RalB were identified and shown to be associated with platelet dense granules 
(Bhullar et al. 1998). Platelet activation with different agonists, including thrombin, leads 
to a rapid and strong activation of Ral in a Ca2+ dependent manner (Wolthuis et al. 1998). 
In permeabilized platelets, the recombinant Ral-interacting domain of Sec5, the 
downstream effector of RalA in exocyst complex was used and the serotonin release from 
dense granules was inhibited. These data suggest that Ral-exocyst play a role in 
regulating platelet dense granule release (Kawato et al. 2008). 
Rap: Rap GTPases play a key role in integrin activation, the regulation of cell-cell 
contact, the formation of cell adhesion, the cell polarity, and the control of exocytosis 
(Frische et al. 2010). The Rap family consists of 2 rap1 genes and 3 rap2 genes. Rap1B 
and Rap2B are expressed in platelets, in which Rap1B is the most abundant form; 
consisting of around 90% of total Rab proteins (Torti et al. 1994). Upon stimulation of 
human platelets with different agonists, including thrombin, Rap1 is rapidly activated. 
This activation of Rap1 requires an increase in intraplatelet Ca2+ (Greco et al. 2004), and 
is not dependent on integrin ‘outside-in’ signaling (Franke et al. 2000). In the murine 
model, Rab1B deficiency results in bleeding and aggregation defect. Stimulated with 
ADP or PAR4 peptide, platelets lacking Rap1B, had a defect in the activation of Integrin 
αIIbβ3 and spreading on fibrinogen (Chrzanowska-Wodnicka et al. 2005). Shattil and 
colleagues defined the importance of Rap1 for αIIb/β3 activation. They showed that 
Rap1-GTP-dependent talin recruitment to β3 integrin by RIAM is required for αIIb/β3 
activation (Watanabe et al. 2008). 
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Noonan Syndrome and Ras Signaling 
Noonan syndrome (NS) is a common, autosomal dominant disorder, found by 
Jacqueline Noonan in 1968 (Noonan 1968). The estimated prevalence is between 1:1,000 
and 1:2,500 live births (Nora et al. 1974; Tartaglia et al. 2011) NS is a genetically and 
clinically variable condition that is mainly characterized by unique facial features, high 
forehead, chest deformity, short stature, short neck with excess skin, bleeding diathesis 
and congenital heart defects (Tartaglia, Gelb et al. 2011). The unique facial features 
include: a broad forehead, and low set of posteriorly rotated ears. Cardiac defects involve 
pulmonic stenosis, cardiomyopathy, arterial spetal defects, and ventricle septal defects. 
Bleeding diathesis is common in patients with NS, due to von Willebrand disease, factor 
XI and XII deficiencies, and thrombocytopenia (Sharland et al. 1992; Singer et al. 1997). 
Leukemia, such as juvenile myelomonocytic leukemia (JMML, OMIM 607785) and 
acute lymphoblastic leukemia (ALL), can occur in NS patients (Fukuda et al. 1997; 
Choong et al. 1999). 
 
Molecular and Genetic Aspects of Noonan Syndrome 
As mentioned earlier, Ras proteins are small GTPases that work as a molecular 
switch as they cycle between an active GTP-bound and an inactive GDP-bound form. 
Upon binding of a growth factor to the receptor tyrosine kinase (RTK) such as the 
epidermal growth factor receptor (EGFR), the receptor undergoes autophosphorylation 
and binds to the adaptor protein GRB2 through its src homology domain2 (SH2) domain. 
This results in binding of the GRB2 through its SH3 domain to the GEF protein, son of 
the seven less (SOS), which in turn will be recruited to the plasma membrane. SOS 
protein will catalyse the exchange of the Ras GDP-bound to the Ras GTP bound form. 
The activated Ras GTP binds to its effector molecule, the serine-threonine kinase Raf. 
Activated Raf phosphorylates MEK, which in turn lead to phosphorylation of ERK. 
Binding of ERK to the transcription factors results in initiation of many signaling 
pathways that lead to cell proliferation, differentiation, survival or cytoskeleton 
rearrangements (Figure 3) (Vetter et al. 2001; Donovan et al. 2002). This occurs in the 
nucleated cell. The exact role of Ras signaling in platelets is not completely defined. 
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Mutations in Ras pathway genes (PTPN11, SOS1, Ras, Raf1, MEK) cause NS and its 
associated disorders.  
PTPN11: Ten years ago, the PTPN11 gene was discovered as a major NS disease 
gene (Tartaglia et al. 2001). PTPN11 is a non-receptor protein tyrosine phosphatase, 
encodes for the SHP-2 protein that is important for controlling Ras activation. SHP2 
structure involves N-terminal src-homology 2 domains (N-SH2 and C-SH2), catalytic 
domain (PTP), and a C-terminal domain with unknown function (Hof et al. 1998). The 
PTPN11 mutation is the most common, occurring in around 50% of NS patients. In NS 
patients, the mutation is mainly missense, gain-of-function mutations that lead to 
disruption of the auto-inhibitory interaction between the N-terminal SH2 domain and the 
catalytic phosphatase domain; this result in enhanced phosphatase activity and thus the 
activation of the Ras-MAPK pathway (Tartaglia et al. 2006). Despite the fact that the 
majority of the cases have germline mutations (Kratz et al. 2005), acquired somatic 
mutations have been reported in around one third of the patients (Tartaglia et al. 2003). 
K-Ras and N-Ras: Monomeric GTPases, that as mentioned above alternate 
between the GDP bound or “the off” switch and the GTP bound or “the on” switch, that 
activate downstream signaling. Ras proteins are activated by the GEFs, (SOS1), that lead 
to the release of the GDP bound, and inactivated by GAPs which lead to increase the 
intrinsic GTPase activity. The Ras subfamily was reported to be rarely associated with 
heterozygous germline mutations in each of the three Ras members: H-, K-, and N-Ras 
(Tartaglia, Martinelli et al. 2006). The incidence of K-Ras mutations is low in patients 
with NS, around 2-4% and associated with variable but severe phenotype (Noonan 1994; 
Zenker et al. 2007). There are two splice variants for K-Ras: K-RasA that is tissue-
specific and restricted developmentally, and K-RasB, that is ubiquitously expressed. 
Several K-Ras mutations have been identified in NS patients. These mutations are mainly 
gain-of-function mutations that lead to increase in the downstream signaling of the 
Ras/MAPK pathway, either by mutations that decrease the intrinsic and GAP GTPase 
activity (Noonan 1994; Osio et al. 2005) so Ras is locked in the GTP form, or by 
mutations that lead to by decrease the affinity of nucleotide binding affinity (Schubbert et 
al. 2007). These mutations lead to an increase in the GTP-bound “active” form of K-Ras, 
however, these mutations that lead to the elevation of the downstream signaling cascades, 
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are less frequent than the mutations occurring in the oncogenic K-Ras that lead to cancer 
(Osio, Dahlgren et al. 2005). Two germline missense mutations of N-Ras (Thr50Ile and 
Gly60Glu amino acid changes) have been identified in NS patients (Cirstea et al. 2010). 
These mutations also enhance the activation of Ras/MAPK pathway. 
Sos: A member of GEFs proteins that mediates the activation of Ras proteins after 
the activation of tyrosine kinase receptors. They facilitate the conversion of the inactive 
GDP-bound form to the active GTP-bound form of Ras, by catalyzing the release of GDP 
from Ras (Quilliam et al. 1995). In Ras signaling, there are two isoforms: SOS1 and 
SOS2. Mutations in SOS1 gene are considered to be the second largest common 
mutations in NS patients, accounting for around 20% (Tartaglia et al. 2007; Zenker et al. 
2007). Around half of the SOS1 mutations are amino acid substitution in the short helical 
linker that connects the plekstrin homology (PH) and the Ras exchanger motif (REM) 
domains. Other mutations identified are located within the PH domain, and the last 
cluster of mutations has been identified at the interacting regions of the Dbl homology 
domain and REM domains. Most of these mutations affects the structure which in turn 
affect the maintenance of the catalytically autoinhibited conformation, leading to gain of 
function and enhancing Ras and ERK activation (Roberts et al. 2007; Tartaglia, 
Pennacchio et al. 2007). Heterozygous NS patients with SOS mutations show distinctive 
phenotypes of ectodermal abnormalities that are associated with some cognitive 
disabilities and short stature (Roberts, Araki et al. 2007; Zenker, Horn et al. 2007). 
Raf1: There are three members of effector proteins have been identified: Raf1, 
ARaf and BRaf (Wellbrock et al. 2004; Leicht et al. 2007). Once activated by the tyrosine 
kinase receptor, they phosphorylate and activate the downstream signaling pathway of 
Ras/MAPK, MEK1 and MEK2, which activates ERK1 and ERK2. Somatic mutations 
occur mostly in BRaf since it has more kinase activity, and mainly occur in malignant 
melanomas, thyroid, colorectal and ovarian cancers, while ARaf and Raf1 missense 
mutations are observed rarely in malignancies. In NS patients, Raf1 mutations occur 
between 5-15% (Pandit et al. 2007; Razzaque et al. 2007). These mutations in Raf1 affect 
residues located in three different regions of the protein. The first group of mutations, 
which account for the majority of the mutations, involve the N-terminal consensus 14-3-3 
recognition sequence or residues near it. The second group involve residues within the 
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activation segment region of the kinase domain. The third group of mutations involve two 
adjacent residues located at the C-terminus. Most of these mutation lead to increase in the 
activation of Ras/MAPK pathway (Pandit, Sarkozy et al. 2007; Razzaque, Nishizawa et 
al. 2007), while the mutations in the activation segment lead to impairment of the 
Ras\MAPK pathway. These mutations in BRaf are clinically associated with a defect in 
neonatal growth and difficulties in feeding, and in cognitive function (Sarkozy et al. 
2009). Their phenotype is more severe than those caused by PTPN11 and SOS1 
mutations. There are more than 40 germline missense BRaf mutations have been 
identified to date. They are clustered in the cysteine-rich domain and in the amino-
terminal domain and in the activation segment of the kinase domain.  
MEK1: MEK1 and MEK, the effectors of Raf proteins are kinases that are 
essential to phosphorylate ERK proteins at tyrosine and serine/threonine residues (Zheng 
et al. 1993). One germline missense mutation in MEK1 has been reported in two 
unrelated patients with a phenotype that fits NS (Nava et al. 2007). There is no data on 
the effect of this mutation on MEK1 function and Ras\MAPK pathway. 
Summary:  
In platelets, the contribution of several Ras GTPases proteins has been identified. 
Upon agonist activation such as thrombin or collagen, platelets are activated and the 
GTPases proteins then initiate cytoskeletal remodeling and activation of integrin. These 
functions are very important for maintaining the physiological function of platelets in 
adhesion and aggregation and thus in retaining the integrity of the vessel wall. However 
the exact role of Ras proteins in platelets is not fully understood to date. Therefore using 
NS patients that have mutations in Ras signaling pathway gives us a novel tool to 
understand Ras function in platelets. Chapter Five of this thesis will focus on that. 
 
Thesis Significance 
The focus of this thesis is on understanding the mechanism of platelet secretion 
and its related pathological outcomes. In Chapter Three, the importance of the v-SNARE 
VAMP-8 in atherosclerosis will be discussed. VAMP-8 is known to play an important 
role in platelet secretion, both in vitro and in vivo, by being the primary v-SNARE 
required for platelet secretion. The aim is to study the role of VAMP-8-mediated 
22 
 
 
secretion in atherosclerosis. The following chapter focuses on the SNARE regulatory 
protein, Munc18b. The exact role of Munc18b in platelet secretion was not fully 
characterized in the literature; therefore we sought to understand if Munc18b plays a role 
in the regulation of platelet exocytosis. In Chapter Five the focus is on the role of the Ras 
GTPase in platelet secretion using NS patients as a tool to understand the signaling 
cascade affected by mutations of this protein and its related upstream and downstream-
effectors and the effect of that on platelet function. 
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Dense Granule α-Granule Lysosome 
Nucleotides: 
- ATP 
- ADP 
 
Amines: 
- Serotonin (5-HT) 
- Histamine 
 
Bivalent cations: 
- Calcium 
- Magnesium 
Adhesive glycoproteins: 
- Fibrinogen 
- Fibronectin 
- thrombospondin-1 
 
Platelet specific: 
- Platelet factor 4 (PF4) 
- β- Thromboglobulin (β-TG) 
 
Angiogenic factors: 
- VEGF 
- PF4 (inhibitor)  
 
Hemostatic factors: 
- Fibrinogen, factor V, VIII, XI 
- Plasminogen 
- Plasminogen activator 
inhibitor-1 
 
Membrane proteins: 
- P-Selectin 
- CD63 (LAMP-3) 
 
Others:  
- IgG, IgM 
- Albumin 
Acid phosphatase 
 
β–hexosaminidase 
 
Acid hydrolases 
 
α-fucosidase 
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Table 1-1: Platelet Secreted Granule Content. (Modified from Smyth et al. (Smyth, 
McEver et al. 2009). Listed are some examples of platelets granule content from dense 
granules, α-granules, and lysosomes. 
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Table 1-2: Platelet Agonists and their Corresponding Receptors. 
Presented in this table are some examples of platelet agonists and their corresponding 
receptors. 
 
 
 
Platelet Agonist 
 
Platelet Receptor 
Thrombin PAR1 and PAR4 
ADP P2Y12 and P2Y1 
Thromboxane A2 Thromboxane 
Collagen GPVI 
Fibrinogen αIIbβ3 
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Figure1-1: Molecular Machinery of SNARE-Mediated Membrane Fusion. 
Membrane fusion occurs in several steps. Briefly, Rab-GTPase proteins (yellow) mediate 
the trafficking of the vesicle to the target membrane. The v-SNARE, VAMP (pink) on the 
vesicle membrane interacts with the t-SNARE, syntaxin (blue) and SNAP-25 (green) on 
the target membrane to form a heterotrimeric (7S) complex that spans the two bilayers 
and mediates membrane fusion and release of vesicle (granule) content (cyan). After 
membrane fusion, NSF (purple) disassembles the 7S complex, and SNAREs proteins are 
then recycled for more rounds of fusion events. 
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Figure 1-2: Ras-MAPK signaling pathway and associated mutations with NS. 
The binding of a growth factor to the receptor tyrosine kinase (RTK) leads to 
phosphorylation of GRB2, which in turn binds SOS (guanosine nucleotide exchange 
factors (GEFs)) leading to the exchange of the GDP to GTP and thus activation of the 
Ras protein. The activated Ras-GTP in turns activates RAF and downstream effectors 
MEK and ERK, which lead to activation of several signaling pathways that are, involved 
in cell proliferation, differentiation and cytoskeleton rearrangements. 
 
 
 
 
Copyright © Rania Al Hawas 2012 
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Chapter Two 
Materials and Methods 
 
Antibodies 
Antibodies to SNARE Proteins 
Rabbit anti-human endobrevin/VAMP-8 polyclonal and rabbit anti-human 
VAMP-7 polyclonal antibodies were generated in our laboratory using recombinant 
version of the following antigens respectively: cytoplasmic domain of VAMP-8 (1-73 aa) 
and the longin domain of human VAMP-7 (1-120 aa). Anti-synaptobrevin VAMP-2 
monoclonal antibody (CL69.1) and rabbit anti-endobrevin/VAMP-8 polyclonal antibody 
was from (Synaptic System, Goettingen, Germany). Sheep anti-cellubrevin/VAMP-3 
polyclonal antibody was a generous gift from Dr. Jeffery Pessin (Stony Brook University, 
Stony Brook, NY). Anti-SNAP-23, anti-syntaxin-2 and -4 polyclonal antibodies were 
generated in the Whiteheart laboratory as described in (Chen, Bernstein et al. 2000).  
 
Antibodies to SNARE Proteins Regulators 
Munc18a/STXBP1 monoclonal antibody was purchased from Synaptic System. 
Rabbit anti-human Munc18b/STXBP2 polyclonal antibody was generated in our 
laboratory using the full recombinant protein of Munc18b. Rabbit anti-
Munc18c/STXBP3 polyclonal antibody was generated in our laboratory. 
Rabbit anti-Munc13-4 A and anti Munc13-4 C polyclonal antibodies were 
generous gifts from Dr. Christian Wimmer (Basel Institute of Immunology, Basel, 
Switzerland). They were generated by, injecting the rabbits with maltose binding protein 
(MBP), tagged domain A (36-349 aa), and tagged domain C (703-975 aa) respectively. 
Anti Munc13-4 monoclonal antibody was from (Synaptic System). Anti-mouse Rab27a 
monoclonal antibody was from (BD Biosciences, San Jose, CA).   
 
Other Antibodies 
Monoclonal anti-mouse Ras antibody was purchased from Millipore (Billerica, 
MA). Monoclonal anti-ß-actin antibody was from Sigma-Aldrich (St. Louis, MO). A 
paired monoclonal platelet factor 4 (PF4) antibodies were used for the Enzyme-Linked 
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Immuno Sorbent Assay (ELISA); a monoclonal anti-human PF4 antibody that was used 
to assay human PF4, was used as the capture antibody (R&D Systems, Minneapolis, 
MN), and the biotin conjugated rabbit anti-human PF4 polyclonal antibody was used as 
the detection antibody (Leinco Technologies Inc., St. Louis, MO). Fluorescein 
isothiocyanate (FITC) labeled anti-human P-Selectin monoclonal antibody (AK-4) and 
FITC-labeled anti-mouse P-Selectin monoclonal antibody (RB 40.34), were from BD 
PharmingenTM (BD Bioscience, San Jose, CA). Alkaline phosphatase conjugated 
secondary anti-mouse, anti-rabbit, anti-rabbit protein-A, anti-sheep, anti-goat, IgGs were 
purchased from (Sigma-Aldrich, St. Louis, MO). FITC conjugated anti-mouse, anti-rat 
and anti-rabbit IgGs were from Vector Laboratories (Burlingame, CA).  
 
Reagents 
Acid citrate dextrose (ACD) tubes used for blood collection (BD Vacutainer R) 
were obtained from BD Diagnositc (Sparks, MD). Formaldehyde (70%) was purchased 
from Electron Microscopy Sciences (Hatfield, PA). EDTA-free protease inhibitor 
cocktail was purchased from Roche (Indianapolis, IL). Platelet activation inhibitor, 
prostaglandin I2 (PGI2) was obtained from Cayman Chemical (Ann Arbor, MI). Agonists 
used for platelets activation, human plasma thrombin and ADP were purchased from 
Chrono-log (Havertown, PA), while convulxin, the snake venom toxin was purchased 
from Centechem Inc. (Norwalk, CT). Mouse cytokines detection kit was obtained from 
Millipore (Billerica, MA). The Avidin Biotin Complex (ABC) immunostaining kit was 
from Vector (Burlingame, CA). 
 
Methods 
Mouse Strain Construction and Genotyping 
VAMP-8-/- mice on a mixed genetic background (C57BL/6J and 129Sv) were 
generously provided by Dr. Wanjin Hong (Institute of Molecular and Cellular Biology, 
Proteos, Singapore). ApoE-/- mice (C57BL/6J) were obtained from the Jackson laboratory 
(Bar Harbor, Maine). Four experimental groups were produced by crossing VAMP-8-/- 
and ApoE-/- mice: ApoE-/- (control for atherosclerosis), VAMP-8-/- (control for secretion 
defect), VAMP-8+/+/ApoE+/+ (wild type), and VAMP-8-/-/ApoE-/- (test group). Mice were 
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maintained on normal chow for 50 weeks. A 2-millimeter piece of each mouse-tail was 
used to extract the DNA. Genotyping was performed using Polymerase Chain Reaction 
(PCR). VAMP-8 genotyping was described in (Wang, Ng et al. 2004), wild type and 
mutant primers were used as follows: 
Wild type primers: 5′-GATCCTCTGCTGCCCGGCCTAAT-3′ and 5′-
CCGTGGCTTCCAAGTCCTCTGTC-3′ 
Mutant primers: 5′-GATCCTCTGCTGCCCGGCCTAAT-3′ and 5′-
GCCTGCAAAGGGTCGCTACAGAC-3′. 
ApoE genotyping was performed as previously described (Zhang et al. 1992). Wild type 
and mutant primers were used as follows: 
Forward primer: 5’ –TGTGACTTGGGAGCTCTGCAGC-3’  
Neo NTR: 5’-GCCGCCCCGACTGCATCT-3’ 
Reverse primer: 5’ –GCCTAGCCGAGGGAGAGCCG-3’ 
For the acute studies, VAMP-8 mice were backcrossed to C57BL/6J background.  
VAMP-8+/-/ApoE+/- progeny were selected based on the genotype and the color (brown 
mice are excluded). These mice were again crossed with C57BL/6J mice and the 
selection process was for a total of 10 generations alternating male and female C57BL/6J 
mice at each breeding time. The resulting VAMP-8+/-/ApoE+/- progeny was then crossed 
to make the strains needed for the acute studies. At 8 weeks of age, mice fed chow 
supplemented with saturated fat 42% and 0.15% cholesterol (diet no. TD88137; Harlan 
Teklad, Indianapolis, IN). Then, lesion size was examined at 15 weeks. Both male and 
female mice were included in the study. All procedures were carried out under a protocol 
approved by the University of Kentucky Institutional Animal Care and Use Committee 
(IACUC). 
 
Human Platelets Preparation  
Washed human platelets were isolated either from fresh banked platelets obtained 
from Kentucky Blood Center (Lexington, KY), or from whole blood that was diluted 2:1 
with HEPES- Tyrode’s buffer (20 mM HEPES/KOH, pH 6.5, 128mM NaCl, 2.8 mM 
KCl, 1 mM MgCl2, 5mM D-glucose, 12 mM NaHCO3, 0.4 mM NaH2PO4), with the 
addition of 0.37 units/mL apyrase (Sigma-Aldrich), 100 ng PGI2 (Sigma-Aldrich), and 
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1mM EGTA, by centrifugation at 150 x g for 10 minutes at room temperature to remove 
red blood cells. Platelets pellet was collected by centrifugation at 900 x g for 10. The 
pellet then was washed with HEPES- Tyrode’s buffer (pH 6.5) containing 0.37 units/mL 
apyrase, 100 ng/mL PGI2, and 1mM EGTA. Washed platelets were then suspended with 
HEPES- Tyrode’s buffer (pH 7.4). 
 
Murine Platelets Preparation 
To collect blood from the mice heart, mice were euthanized by carbon dioxide 
inhalation. Then the heart was exposed, and the blood was withdrawn from the right 
ventricle, using a 26-gauge needle attached to a 1 mL syringe (BD Diagnostics, Sparks, 
MD) containing 100 µL of 3.8% sodium citrate. The blood (1 mL) then was pooled and 
diluted with an equal volume of phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM 
KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, (pH 7.4)) containing 0.37 units/mL apyrase 
and 100 ng/mL PGI2.  To collect the PRP, whole blood was centrifuged at 250 x g for 10 
minutes. Washed platelets were collected by centrifugation at 120 x g for 10 minutes in 
presence of 0.37 units/mL apyrase and 100 ng/mL PGI2. Followed by washing platelet 
pellet with HEPES-Tyrode’s buffer (pH 6.5) containing 0.37 units/mL apyrase, 100 
ng/mL PGI2, and 1mM EGTA. Platelets were then suspended with HEPES- Tyrode’s 
buffer (pH 7.4). 
 
Platelet Counting 
To count platelets, the Z2 coulter counter (Beckman Coulter, Inc., Miami, FL) 
was used. Washed platelets prepared as described above, were diluted in HEPES- 
Tyrode’s buffer (pH 7.4) 1:20.000. The final count was based on the average of three 
counts. The concentration of platelets was adjusted as indicated in each experiment.  
 
Platelet Aggregometry 
Aggregation of washed platelets prepared as described above, was measured 
using a Chrono-Log Model 460VS Lumi-aggregometer (Havertown, PA). Using 500 µL 
and 250 µL of human and mice platelets respectively, siliconized glass cuvette with a 
metal stirring bar (Chrono-log), spinning at 800 rpm for 3 minutes at 37oC. Agonists were 
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added for indicated period of time. The aggregation traces were monitored using Model 
810 Aggro/Link computer interface and Aggro/Link software (Chrono-log).  
 
Platelet ATP Release 
Using Chrono-Log Model 460VS Lumi-aggregometer (Havertown, PA), ATP 
release from platelets dense granule was measured. Washed platelets, 500 µL and 250 µL 
of human and mice platelets respectively, were incubated with luciferin/luciferase reagent 
(Chrono-Log) according to the manufacturer’s instructions. The mixture was incubated at 
37oC for 2 minutes with stirring prior to the addition of agonist or ATP standard.  Upon 
platelets activation, the ATP released by the platelet dense granules binds with luciferin-
luciferase and generates light with 560 nm peak. Luminescence traces were acquired 
simultaneously with aggregation on the Chrono-Log system. 
 
Platelet Secretion Assay 
 Washed human platelets were labeled with 2 µCi/mL [3H]5-HT (Perkin-Elmer 
Cetus Life Sciences, Boston, MA) for 45 minutes at 37°C, followed by washing with a 
calcium-free HEPES/Tyrode's buffer (pH 7.4) in the presence of 3 µg/mL apyrase. 
Platelets pellet were resuspended with HEPES/Tyrode's buffer (pH 7.4), and the 
concentration of platelets were adjusted to 2.5 × 108/mL.  
For thrombin titration experiments, different concentrations of thrombin (Chrono-
Log) were added to stimulate platelets as indicated. To stop the reactions, a twofold 
excess of hirudin (Sigma-Aldrich) was added. For the time-course experiments, 0.05 
U/mL thrombin was added for the indicated periods of time, and o stop the reaction, 0.1 
U/mL hirudin was added. The samples were centrifuged at 13,800 × g for 1 minute. After 
removing the supernatant, platelet pellets were lysed with an equal volume of lysis buffer 
(PBS, pH 7.4, 1% Triton X-100) and kept on ice for 1 hour.  
Platelet secretion assays were performed using equal volumes of the supernatant 
and the pellet, from the three granule contents, using the following markers: [3H]5-HT for 
dense core granules (DC), platelet factor 4 (PF4) for alpha granules, and β-
hexosaminidase for lysosomes as previously described (Schraw, Rutledge et al. 2003). 
For the dense granule release, 25 µL of platelet supernatant and of the pellet were added 
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to 5 mL of scintillation cocktail solution, and the analysis of the samples were carried out 
using Tri-Carb2100TR liquid scintillation analyzer (Beckman, Fullerton, CA). For α–
granule secretion, PF4 was assayed using ELISA method according to the manufacturer’s 
instruction (R&D Systems). Lysosomal secretion was detected by measuring the 
enzymatic activity of hexosaminidase. Using 96 well plates, 6 µL of supernatant and 3 
µL of the pellets were mixed with 100 µL of citrate-phosphate buffer (53.4 mM citric 
acid, 93.2 mM Na2HPO4, pH 4.5) in the presence of 10 mM p-nitrophenyl-N-acetyl-β-D-
glucosaminide). The plate was sealed and incubated at 37oC for 18 hours. The reaction 
was stopped by adding 100 µL of 0.08 N NaOH. To determine the optical density of each 
well, a Biotek Elx808 plate reader (BioTek Instruments Inc., Winooski, VT) was used at 
405 nm. The secretion assays data were analyzed by dividing the supernatant fraction by 
the total fraction (supernatant plus pellet) to determine the percent of release for each 
granule marker.  
 
Flow Cytometry Analysis 
Washed human platelets (20 µL) were incubated with (4 µL) FITC-conjugated 
PAC-1 or PE-conjugated anti-CD41a monoclonal antibodies for 15 minutes at 37°C. 
Platelets were stimulated with thrombin (0.1 U/mL) for 3 minutes at room temperature. 
The reaction was stopped with the addition of a 2-fold excess of hirudin. The platelets 
were 10-fold diluted by adding HEPES-Tyrode’s buffer (pH 6.5). The samples were 
transferred into polystyrene FalconTM tube (BD Biosciences). Fluorescent intensity was 
determined using FACScanTM flow cytometer. The voltages for forward light scattering 
(FSC; E-01/linear) and side light scattering (SSC; 450/linear) were optimized to measure 
platelet population. The voltages for excitation of blue (FITC) and red (PE) channels 
were adjusted to detect the fluorescence intensity.  The data was plotted as a histogram 
with statistical values using CellQuestTM (BD Biosciences) analysis software. 
 
Electron Microscopy of Platelet Morphology 
 Washed platelets prepared as described above, were used either as resting or 
stimulated with 0.1 U/mL of thrombin for 20 minutes at room temperature. To stop the 
reaction, an equal volume of 6% glutaraldehyde (Electron Microscopy Sciences) in 0.2 M 
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Sorenson’s phosphate buffer (16.2 mg/mL KH2PO4, 3.76 mg/mL Na2HPO4, pH 8.0) was 
added to the platelet suspension as previously described (Chen, Bernstein et al. 2000; 
Ren, Barber et al. 2007). The samples were incubated at 4°C for 1 hour, followed by 
washing three times for 5 minutes with 0.1 M Sorenson’s buffer by spinning the samples 
at 3,000 × g for 2 minutes. Platelet pellet was then resuspended in 300 µL of 1% OsO4 
dissolved in 0.1 M Sorenson’s buffer and incubated for 30 minutes on ice.  
Samples were washed twice with 0.1 M Sorenson’s buffer and dehydrated in a 
serial ethanol washes (50%, 70%, 80%, 90%, 100%, and absolute ethanol) for 5 minutes 
at room temperature. The platelets were incubated with propylene oxide and infiltrated 
overnight in a 1:1 mixture of propylene oxide and Spurr’s resin (10 g vinyl cyclohexane 
dioxide (VCD), 6 g DER epoxy resin, 26 g nonenyl succine anhydride (NSA) with final 
addition of 0.4 g dimethylaminoethanol (DMAE)). Samples were washed in Spurr’s resin 
for 1 hour at room temperature and then embedded in 200 µL Spurr’s resin and 
polymerized in a 60oC incubator for two days. After the blocks were polymerized, they 
were sectioned and mounted on copper grids. The sections were then stained with uranyl 
acetate and examined using Philips Tecnai 12 transmission electron microscope (FEI, 
Hillsboro, OR) and images were captured with Gatan Digitalmicrograph software 
(Pleasanton, CA). 
 Alternatively, for better identification of platelet dense granules (Schraw et al. 
2004), a slight modification of the procedure was employed in the fixation step. An equal 
volume of 0.1% glutaraldehyde in White’s saline (120 mM NaCl, 5 mM KCl, 2.3 mM 
MgSO4, 3.2 mM Ca(NO3), 6.5 mM NaHCO3, 0.42 mM Na2HPO4, 0.19 mM KH2PO4, 
0.0005% phenol red) to the platelet suspension for 15 minutes at 37°C. The platelets were 
centrifuged at 3,000 × g for 2 minutes and incubated in ice-cold 3% glutaraldehyde in 
White’s saline at 4°C for 1 hour. After three washes with White’s saline and the platelets 
were osmicated in 1% OsO4 in White’s solution. The rest of the steps were the same as 
described above. This modification was known to generate a stable fixation of granule 
contents and provides a better identification of dense granules (White 2004). 
Dissection of Mouse Aorta and Heart 
Mice were anesthetized using intraperitoneal injection (i.p.) of ketamine/xylazine; 
100 mg/kg (Fort Dodge Animal Health, Fort Dodge IA) . Mice were then placed on their 
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dorsal side where the skin can be cut from the base of the abdomen to the underside of 
the chin. To visualize the heart, two cuts made under each side of the ribs, which was 
later lifted up. The blood was withdrawn as described above, for lipid analysis. Perfusion 
of the heart and aorta was performed using a cannula in the left ventricle with 20 mL of 
PBS to clear the heart. The entire aorta and the heart were dissected and processed with 
either en face or Oil Red O staining techniques for quantifications. 
 
Total Cholesterol Measurement 
One hundred microliters of blood was collected by cardiac puncture from 
anesthetized mice as described above. Serum was separated to measure the concentration 
of total cholesterol and triglycerides using a commercially available enzymatic assay kit, 
Cholesterol E enzymatic kit (Wako Chemical Company, Richmond, VA). The 
distribution of lipoprotein cholesterol was measured using, fast protein liquid 
chromatography (FPLC) gel filtration (GE Healthcare, Piscataway, NJ) on a single 
Superose 6 column was used as described previously (Daugherty et al. 2000). The 
collected fractions were assayed with the Cholesterol E enzymatic kit (Wako Chemical 
Company, Richmond, VA).  
 
Plasma Glucose Measurement  
The level of plasma glucose was measured using the quantitative coupled reaction 
enzymatic kit from Sigma-Aldrich as described by Raabo et al. (Raabo et al. 1960). 
Glucose was oxidized to gluconic acid and hydrogen peroxide by the addition of glucose 
oxidase. The substrate, o-dianisidine was added to the reaction, and it interacted with 
hydrogen peroxide to form a colored product in the presence of peroxidase enzyme. 
Concentrations of the glucose were proportional to the intensity of the pink color product 
that was measured at 425 nm. The 2X stock peroxidase-glucose oxidase (PGO) enzyme 
was prepared by dissolving one capsule in 50 mL of distilled water.  The substrate, o-
dianisidine dihydrochloride (50 mg) was dissolved in 20 mL distilled water.  The 
working solution was prepared with 10 mL distilled water, 10 mL 2X PGO enzyme 
solution, and 0.32 mL of o-dianisidine dihydrochloride solution. Using 96-well plate, the 
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reaction started after the addition of 250 µL of working solution, 24 µL of distilled water 
and 1 µL of plasma, and incubated for 30 minutes at 37oC then read at 425 nm.  
 
Quantification of the lesions in the aorta using en face technique 
Whole aorta from each mouse was dissected, and aortic tissue was removed from 
the ascending aorta to the ileal bifurcation and fixed in 4% paraformaldehyde in 
Phosphate Buffer Saline (PBS) overnight at room temperature. Adventitial tissue was 
removed under dissecting microscope and the intimal part of the aorta was exposed after 
performing a longitudinal cut through the entire aorta. The en face method was used to 
quantify the lesions in the intimal area of the aorta (Daugherty et al. 2003). Briefly, the 
opened aorta was pinned on a black background and images of the atherosclerotic lesions 
in the aortic arch to the upper thorax (around 3mm) were captured to computer using a 
digital camera that is connected to the dissecting microscope. Atherosclerotic lesions on 
the aortic arch and thoracic area were outlined using Image-pro software (Media 
Cybernetics, Silver Spring, MD) and are represented as the sum of the lesion areas 
divided by the area of the vessel for each region. 
 
Quantification of the lesions in the aorta using Oil Red-O staining technique 
 The heart was dissected as described above for quantifications of the lesions in 
the aortic root. After PBS perfusion in the left ventricle of the heart, approximately 70% 
of the lower ventricular mass was severed and the upper cardiac portion was embedded 
in, a tissue freezing medium O.C.T. (Optimal Cutting Temperature; Electron Microscopy 
Sciences, and frozen at -20°C. Serial sections (10 µm) were collected on 10 slides 
containing 9 sections each that are 80 µm apart. The sections were stained with Oil Red 
O (neutral lipid stain) and counterstained with hematoxylin and eosin (Vector), then 
mounted with glycerol/gelatin (Sigma-Aldrich). The surface area covered by lesions was 
measured using Image-Pro software (Media Cybernetics, Silver Spring, MD). To obtain 
the medial area, the inner elastic lamina (intima-medial border) was marked and 
subtracted from the outer elastic lamina (medial-advential border). Mean medial area was 
measured from 9 to 15 sections per mouse. All measurements for the ascending aorta 
were calibrated to a 1 mm section of a hemacytometer/40 x magnification. 
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Statistics 
Statistical analyses were performed using SigmaStat program (SPSS Inc.). The 
measurements for the atherosclerosis studies are represented as the mean ± S.E.M; using 
one Way ANOVA for the four different mice genotypes.  
 
Tissue immunostaining  
The frozen serial sections of aortic root were obtained as described above. For 
immunostaining, the sections were fixed in chilled absolute ethanol for 10 minutes, as 
previously described (Lu et al. 2007). A Fisher Microprobe system was used for 
immunostaining. The slides were incubated with indicated different concentrations of the 
primary rabbit anti-endobrevin/VAMP-8 polyclonal antibody (Synaptic Systems) for 30 
minutes at 37°, followed by incubation with the secondary goat anti rabbit biotinylated 
antibody (1:500) (Vector) for 30 minutes at 37°. The antigen-antibody binding was 
determined by AEC chromagen substrate using ABC kit (Vector). Controls included, no 
primary, no primary and no secondary, and non-immune sera or IgG. Images were 
acquired with a 20x objective lens of a Nikon Eclipse E600 scope and a digital camera 
DXM1200F (Nikon).  
  
Preparation of GTPase binding domain recombinant protein  
Plasmid containing GTPase binding domain, pGEX-4T-3/Raf-Ras binding 
domain (RBD) was from Johan Bos Netherlands (University of Groningen, Groningen, 
Netherlands). The plasmid was transformed into the RosettaTM(DE) E coli strain that 
harbor a plasmid (pRARE) contains a rare tRNA sequences (Novagen, Gibbstown, NJ). 
After adding 20 mL of frozen stocks to 2 x 50 mL Luria-Bertani (LB) broth with 
antibiotics (ampicilin: 100 mg/mL and chloroamphenicol: 35 mg/mL), the culture was 
incubated overnight.  The culture was centrifuged and the pellet was resuspended in 10 
mL LB media, followed by transferring to 2 x 2L LB media and incubating it at 37°C in 
the presence of antibiotics until OD600 reached to 0.8 to 1.2. The recombinant protein was 
induced for 4 hours in the presence of 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG). The cells were then harvested by centrifugation using the SLC-4000 rotor 
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(Thermo Scientific Watham, MA) at 5000 rpm for 7 minutes. The bacterial pellet was 
resuspended in 200 mL of ice-cold 1X PBS, and transferred to 500 mL bottles and 
centrifuged again at 6000 rpm for 7 minutes, and stored at -80°C. The bacterial pellet was 
resuspended in ice-cold PBS (4 mL per 1 g in weight) with 1X protease inhibitor cocktail 
plus 1 mM DTT. The cells were lysed using three passages of French Press (12,000 psi, 
700 - 1500 cell pressure at high ratio) and centrifuged at 4°C for 1 hour at 50,000 rpm in 
the Beckman Ti70 rotor with low break. The supernatant was filtered using 0.2 mm nylon 
filter (Fisher Scientific, Hampton, NH). The recombinant proteins were stored at -80°C 
after 10% sterile glycerol was added and rotated for 10 minutes at 4°C. The binding 
affinity was determined by, glutathione agarose beads binding assay. Different 
concentrations of recombinant proteins (10, 20, 50, 100, 200, 300) were incubated with 
10 mL beads for 1 hour at 4°C, followed by washing of the beads complex for three times 
with HEPES wash buffer. The proteins were eluted by the addition of 2× SDS sample 
buffer and boiling the samples. The binding was analyzed by 10% SDS-PAGE. 
 
Ras Pull-Down Assay 
 For platelets preparation, washed human platelets (500 µL), were incubated at 
37oC using Aggregometry for 3 minutes followed by the addition of different 
concentrations of agonist as indicated in the experiment, for 5 minutes. The reaction was 
stopped by, adding cold 2x lysis buffer (20 mM HEPES-KOH, pH 7.4, 128 mM NaCl, 9 
mM MgCl2, 2% Triton X-100, 20% glycerol, 2 mM benzamidine, 2x protease inhibitor 
cocktail). Platelet lysate in the cuvette was sealed with parafilm and instantly frozen in 
ethanol-dry ice chamber and stored at -80oC, not longer than 24-48 hours before the pull 
down assay experiment. For resting platelets lysate, the same steps above were followed 
except for the addition of the agonist. 
For pull down assay, after thawing the frozen platelet lysate on ice, they were 
transferred to 1.5 mL cuvette tubes. To clear the lysates from the cytoskeleton 
components, lysates were centrifuged at 13,000 rpm for 5 minutes at 4oC. The clear 
lysate was then incubated with 10 µL glutathione-agarose beads bound to glutathione-S-
transferase (GST)-fusion protein, which has a specific domain to bind to the GTP-bound 
form of Raf-Binding-Domain (RBD) for human Ras, for 1 hour at 4oC, and slowly 
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rotated. The complex above was centrifuged at 500 x g for 10 seconds, followed by 
washing with HEPES-wash buffer (20 mM HEPES, pH 7.4, 128 mM NaCl, 2 mM 
MgCl2, 1% Triton X-100, 10% glycerol) for three times. The samples were eluted using 
2x SDS sample buffer (130 mM Tris, pH 6.8, 4% SDS, 10% glycerol, 2% β-
mercaptoethanol, 0.02% bromophenol blue), and boiled for 10 minutes. Samples were 
stored at -20oC to be analyzed by western blot. 
 
Western Blotting 
After solubilizing washed platelet lysate in 2x SDS sample buffer, the protein in 
these samples will be separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) (Ornstein 1964) at room temperature for 2 hours at 100 
volts or 1 hour at 200 volts. Proteins were separated based on their molecular weight, 
then blotted on polyvinylidene difluoride (PVDF, Milipore, Bedford, MA) at room 
temperature for 1 hour at 100 volts. To block any non-specific interactions between the 
membrane and the antibody, blots were then blocked with 5% non-fat dried milk in Tris 
Buffer Saline with Tween-20 (TBST; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% 
Tween-20 (Sigma-Aldrich) at room temperature for 1 hour. The blocked membranes 
were incubated with the indicated primary antibody and incubated at room temperature 
for 2 hours or at 4oC overnight. The membranes then were washed three times with TBST 
to remove the unbound antibody. The washed membranes were then incubated with 
secondary antibody that matches the species of the primary antibody, and attached to 
Alkaline Phosphatase (AP) enzyme. The interaction of the primary and secondary 
antibody detected visualized using enhanced chemifluorescent substrate (ECL; Peirce 
ECL detection kit), in which the AP enzyme cleaves the chemiluminescent and the signal 
was acquired with the Typhoon 9400 phosphoimager and quantified with ImageQuant 5.2 
software. 
 
Immunoprecipitation of Platelet SNAREs and its Regulatory Proteins 
Immunoprecipitation (IP) assay was performed; using washed banked platelets, in 
resting or in stimulated condition. To stimulate platelets, 0.1 U/mL of thrombin was 
added to 500 µL of platelets for 3 minutes, with constant shaking by hand at room 
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temperature. For Munc18b IP, resting and stimulated platelets were incubated with 2x IP 
lysis buffer (2% n-Octyl-β-glucopyranoside; 2 mM EGTA; 2 mM EDTA; 100 mM 
HEPES; 150 mM NaCl; 2 mM Na3VO5 and protease inhibitor cocktail (pH 7.4)) on ice 
for 30-60 minutes to lyse the cells. Platelet lysates were centrifuged at 13,000 rpm for 15 
minutes at 4oC to pellet down the cytoskeleton proteins. To clear any non-specific 
binding, platelet lysate were incubated with 5 µg/mL of rabbit IgG (Sigma-Aldrich, St. 
Louis, MO) for 5 minutes at 4oC on the rotator, then 50 µL of Protein A-sepharose beads 
were added, and the mixture was incubated for 30 minutes at 4oC on the rotator. To clear 
the bead complex, the tubes were spun down at 500 x g for 12 seconds. The cleared 
supernatant was then incubated with 20 µL of Munc18b polyclonal rabbit antibody for 2 
hours at 4oC on the rotator, followed by the addition of 60 µL of Protein A-Sepharose 
beads for 2 hours at 4oC on the rotator. The mixture was washed three times with 1x cold 
IP lysis buffer at 500 x g for 12 seconds. The protein was eluted with 2x SDS sample 
buffer by boiling for 10 minutes. Samples were frozen at -80oC and processed within 48 
hours. Western blot technique was utilized to detect Munc18b protein, and for the 
coimmunoprecipitation, syntaxin-11, Munc13-4, Rab 27a, VAMP-8, Munc18a, 
Munc18b, syntaxin-2 and syntaxin-4 antibodies were used.  
Syntaxin-11 IP was performed as indicated above, except in the 2x IP lysis buffer, 
2% Triton X-100 was used instead of 2% n-Octyl-β-glucopyranoside. For the 
coimmunoprecipitation, Munc18b, Munc13-4, Rab 27a, VAMP-8, syntaxin-2 and 
syntaxin-4 antibodies were used. 
 
Generation of Munc18b antibody 
  New Zealand white rabbits were used to generate Munc18b antibody. Human full 
Munc18b protein (1mg) was emulsified in 1 mL Freund’s complete adjuvant (Sigma-
Aldrich, St. Louis, MO) and subcutaneously injected into 10 different sites on both sides 
of the back of the rabbit (100 µL/site). The rabbit was boosted 2 weeks later with 0.25 mg 
of Munc18b protein emulsified in Freund’s complete adjuvant (Sigma-Aldrich) as 
described above. Two weeks following the boost, 30-35 mL of blood was drawn from the 
rabbit ear vein to test for the antibody. The rabbit was boosted again every 2 weeks for 7 
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cycles, and bled 2 weeks after each boost. The blood was centrifuged at 35,000 rpm for 
10 minutes, and the serum was stored as aliquots at -20oC.  
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Chapter Three 
The Role of VAMP-8 in Atherosclerosis 
Introduction 
Atherosclerosis, the leading cause of heart attack, stroke, and peripheral vascular 
diseases, is a complex disease that involves a plethora of cells, such as white blood cells, 
endothelial cells and platelets. Platelets, the first responder of the vasculature, gained this 
expression not only because they are small, discoid cells, that sense the vascular injury, 
and form a clot to stop bleeding, but also due to their secretion of several pro-
inflammatory molecules that lead to manifestation of numerous pathophysiological 
processes in the body, such as atherosclerosis. There is growing evidence of a role for 
platelets in atherosclerosis (Burger and Wagner 2003; Huo, Schober et al. 2003; Gawaz, 
Langer et al. 2005; Sachais, Turrentine et al. 2007). Platelets contain three granules 
(alpha, dense granules, and lysosomes). Secretion of pro-inflammatory and thrombotic 
proteins from these granules contributes to atherosclerosis.  
Platelet secretion is mediated by the soluble N-ethylmaleimide-sensitive factor 
activating protein receptor (SNARE) proteins (Lemons, Chen et al. 1997; Flaumenhaft, 
Croce et al. 1999; Chen, Bernstein et al. 2000). Platelets express two subclasses of 
SNARE proteins, t-SNAREs on the target/plasma membrane, and v-SNAREs on the 
vesicle membrane, and their interaction brings the two membranes together and lead to 
fusion and secretion of the granule content. Among platelets v-SNAREs, our laboratory 
demonstrated that the endobrevin/VAMP-8 is the primary v-SNARE for platelets 
secretion and thrombosis in vitro and in vivo, using VAMP-8 knock out mouse model 
(Polgar, Chung et al. 2002; Schraw, Rutledge et al. 2003; Ren, Barber et al. 2007; 
Graham, Ren et al. 2009). Given the known role of platelets in hemostasis and the 
proposed role of platelet in atherosclerosis, we sought to determine whether the deletion 
of VAMP-8 affects the development of atherosclerosis. For these studies, ApoE-/- mice, 
which are susceptible to atherosclerosis, were crossed with VAMP-8-/- mice to obtain 
four different experimental groups. There are three control groups: ApoE-/- (control for 
atherosclerosis), VAMP-8-/- (control for secretion defect), ApoE+/+/VAMP-8+/+ (normal 
control), and ApoE-/-/VAMP-8-/- (test group). Male littermates from each group were 
evaluated for the development of atherosclerosis at 50 weeks of age using en face 
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examination of the aorta and Oil Red O analysis of the aortic root.  The data demonstrate 
that plaque size was significantly decreased in the aortic root (P= 0.009) in the ApoE-/-
/VAMP-8-/- mice compared with their respective control groups, while in the aortic arch 
there was a trend towards having decreased lesions that did not reach the significant 
difference (P= 0.097).  These data show that the loss of VAMP-8 decreased the 
development of atherosclerotic plaques and suggests that VAMP-8 may play a role not 
only in the late stages of the disease but also in the initiation of atherosclerosis. 
 
Results: 
Mice Characteristics and Diet 
Our laboratory showed that the endobrevin/VAMP-8 is important for platelet 
secretion in vitro, and in vivo. VAMP-8-/- mice platelets, stimulated with thrombin, 
showed a secretion defect from the three granules. In addition, Graham et al. (Graham, 
Ren et al. 2009) showed that VAMP-8 is important for thrombus formation and stability. 
Thus we sought to determine if VAMP-8-mediated secretion plays a role in 
atherosclerosis. VAMP-8-/- mice on a mixed genetic background (C57BL/6J and 129Sv) 
were crossed with ApoE-/- mice (C57BL/6J) to generate a double knock-out mouse 
model: ApoE-/-/VAMP-8-/-. ApoE-/- mice were used as a positive control for 
atherosclerosis. In addition, VAMP-8-/- was used as a negative control, and all were 
compared to wild-type mice. Fifty week old, male mice (Table 3-1) were maintained on 
normal chow and evaluated for the development of atherosclerosis.  This was considered 
a chronic model of atherosclerosis.  
Another group of mice were backcrossed onto a C57BL/6J background for 10 
generations to resolve the mixed background issue.  They were maintained on chow 
supplemented with saturated fat (milk fat 21% wt/wt) and cholesterol (0.15% wt/wt, diet 
no. TD88137; Harlan Teklad) for 15 weeks. These two models were compared because it 
was not clear whether the high-fat diet model might overwhelm any effect that might be 
caused by VAMP-8-deletion. We had originally assumed that the VAMP-8 role could be 
subtle and thus be more apparent in a chronic model of atherosclerosis. However, in the 
acute model, there were several breeding difficulties and the experiments were performed 
only on the ApoE-/- control group for atherosclerosis.  Mouse genotyping was carried out 
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as described in Chapter Two. A 2 mm piece of DNA was used to establish the genotype 
of each mouse using a Polymerase Chain Reaction (PCR).  
Quantification of Lesions in Aortic Arch 
As mentioned earlier, VAMP-8 mediated secretion is important for platelet 
function, and the literature points to the fact that platelet secretion is associated with 
atherosclerotic lesions and some granule cargo, such as P-Selectin and PF4 may 
contribute to plaque development (Dong, Brown et al. 2000; Sachais et al. 2004; Sachais, 
Turrentine et al. 2007). Thus VAMP-8 mediated secretion might play a role in 
atherosclerosis. The mice generated for the chronic studies, were examined for plaque 
development in the aortic arch of the heart. In Figure 3-1B, deletion of VAMP-8 reduced 
the development of lesions in the aortic arch, compared with the control group (Figure 3-
1A), as shown by en face dissection and computer-assisted measurements from 
micrographs. The wild type (Figure 3-1C) and VAMP-8-/- (Figure 3-1D) mice groups had 
no atherosclerotic plaques as expected. 
The size of the plaques in these mice was measured (Figure 3-2) using Image-pro 
software and the data was analyzed using Sigma plot software. There was a difference in 
lesion size (P=0.097) between the ApoE-/-/VAMP-8-/- mice (open triangles) and the 
control group of ApoE-/- (closed triangles). These data suggest that VAMP-8 mediated 
secretion events are important for atherosclerosis. 
 
Quantification of Lesions in Aortic Root 
 An additional measure to evaluate the lesion size in the mice is Oil Red O staining 
of the aortic root. As shown in Figure 3-3B, there was a significant reduction in the size 
of atherosclerotic lesions in ApoE-/-/VAMP-8-/- mice compared to the ApoE-/- control 
group (Figure 3-3A). Both the wild type (Figure 3-3C) and VAMP-8-/- (Figure 3-3D) 
mice groups had no detected lesions.  
 The quantification data for the lesion size in the aortic root (Figure 3-4) indicated 
that there is a significant difference (P=0.009) between the ApoE-/-/VAMP-8-/- mice 
(open triangles) compared to their respective control (closed triangles). The data suggest 
that the loss of VAMP-8 suppresses the development of atherosclerotic lesions in two 
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regions of the aorta and suggest that VAMP-8-mediated secretion plays a role not only in 
thrombosis but also in the development of atherosclerosis.  
 
VAMP-8 Deletion Did Not Have an Effect on the Total Cholesterol 
 It was clearly illustrated above that the deletion of VAMP-8 had an effect on the 
lesion size in atherosclerotic mice. This phenotype might be due to the effect of VAMP-8 
deletion on cholesterol metabolism, thus explaining why the lesions are smaller. To rule 
out this possibility, total cholesterol level was measured. Figure 3-5 shows that there is no 
difference in cholesterol levels between ApoE-/-/VAMP-8-/- mice (open triangles) and 
their respective control of ApoE-/-mice (closed triangles), suggesting that the apparent 
phenotype of decrease lesion size is due to the effect of VAMP-8 on secretion and not the 
cholesterol metabolism. 
 
VAMP-8 Deletion Did Not Have an Effect on Glucose Metabolism 
 Previous studies regarding the effect of VAMP-8 deletion on glucose metabolism 
was controversial. While Hong and colleagues showed that VAMP8 null mice responded 
normally to glucose challenge and suggested that VAMP8 is not required for insulin 
secretion (Wang, Ng et al. 2004), others suggested that the deletion of VAMP-8 had an 
effect on glucose metabolism (Zong et al. 2011). To determine if glucose metabolism was 
affected and thus contributed to the difference in lesion size, total plasma glucose was 
measured using the quantitative coupled reaction enzymatic kit from (Sigma-Aldrich). In 
Figure 3-6, the deletion of VAMP-8 did not have an effect on plasma glucose level in 
ApoE-/-/VAMP-8-/- mice (open triangles) and their respective control of ApoE-/-mice 
(closed triangles). This result suggested that the deletion of VAMP-8 did not have an 
effect on glucose metabolism. 
 
VAMP-8 in Other Cell Types 
 The endobrevin/VAMP-8 deficiency affects the release from platelets (Ren, 
Barber et al. 2007), mast cells (Tiwari, Wang et al. 2008), and pancreas (Wang, Ng et al. 
2004). Among the major cells involved in atherosclerosis are macrophages and 
endothelial cells. In order to detect the presence of VAMP-8 in these cells, western blot 
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analysis was performed. As shown in Figure 3-7A and B, VAMP-8 is expressed in both 
macrophages and endothelial cells. Data in the literature showed that VAMP-8 is also 
important for macrophages secretion (Pushparaj et al. 2009). The expression of VAMP-8 
is not limited to platelets, and thus the atherosclerotic phenotype demonstrated in this 
chapter might suggests that other cells, such as macrophages and endothelial cells play a 
role in atherosclerosis.  
 
VAMP-8 Present in the Lesions of the Aortic Root  (Immunohistochemistry) 
 To demonstrate the presence of VAMP-8 in atherosclerotic lesions, 
immunohistochemistry was performed using aortic root sections from ApoE-/- mice. 
Using different concentrations of anti-VAMP-8 polyclonal antibody: 1:200, 1:5000, and 
1:1000 (Figure 3-8C, D, and E), we showed that VAMP-8 is present in the lesions of 
aortic root. In addition, macrophages were also present in the lesion area (Figure 3-8A). 
This data further suggest that VAMP-8 plays a role in atherosclerosis. 
 
Discussion: 
Studies in the literature suggested a role of platelet secretion in atherosclerosis, 
not only in the late stages but also in early stages of atherosclerosis (Sachais, Higazi et al. 
2004; Sachais, Turrentine et al. 2007). PF4 was detected in early atherosclerotic lesions, 
and it was correlated with the severity of the disease. Li et al. (Data not published-53rd 
ASH Symposium 2010) showed that the deletion of the platelets P2Y12 receptor 
decreases the monocyte infiltration in the aortic root and atherosclerosis. These data 
imply that platelets activation is important for atherosclerosis. In addition the presence of 
PF4 in the lesions of the aorta in the Sachais et al. study reflects the importance of 
platelets chemokines release in the development of atherosclerosis(Sachais, Turrentine et 
al. 2007). In addition, previous work from our laboratory showed that among the v-
SNAREs present in platelets, VAMP-8 was the primary v-SNARE for secretion and for 
thrombosis (Ren, Barber et al. 2007; Graham, Ren et al. 2009). VAMP-8 was required for 
platelet secretion from the three granules, and the stability of thrombus. Putting this 
evidence together, in this chapter we aimed to identify the role of VAMP-8 mediated 
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secretion in atherosclerosis. Therefore, ApoE-/-/VAMP-8-/- mouse model was generated 
(Table 3-1).  
As predicted, the lesion size in the double knockout mice was decreased 
compared to the control group. This phenotype was observed in both aortic arch (Figure 
3-1 and 3-2) and aortic root (Figure 3-3 and 3-4). The double knockout mice showed a 
significant reduction in the lesion size in aortic root area (P=0.009) compared to the 
control group (Figure 3-3). A similar phenotype was observed in the aortic arch area; 
however, this trend did not yet reach statistical significance but may when more ApoE-/- 
animals are added to the study. These data indicate that the deletion of VAMP-8 was 
protective against atherosclerosis.  
Deletion of some genes might have an effect on the body metabolism, and thus 
might contribute to the phenotype in this study. To investigate this possibility, total 
cholesterol was measured. There was no difference in cholesterol levels between ApoE-/- 
/VAMP-8-/- and the atherosclerotic control of atherosclerosis ApoE-/- mice (Figure 3-5). In 
addition, glucose level was determined to see whether VAMP-8 deletion has an effect on 
insulin metabolism. The data presented in Figure 3-6, showed no difference between 
ApoE-/- /VAMP-8-/- and ApoE-/- control groups.  
Since the knockout model in this study is global deletion of VAMP-8, it is not 
certain which of the hematopoietic cells contributed to the present phenotype. Thus we 
examined the presence of VAMP-8 protein in platelets, macrophage and endothelial cells. 
VAMP-8 was expressed in all these cell types with the majority in platelets (Figure 3-7). 
To further characterize the importance of VAMP-8 in atherosclerosis, the 
immunohistochemistry experiments (Figure 3-8) indicated that VAMP-8 present in the 
aortic root, indicating that it participates in the process of lesion development through its 
expression by the cells in that region. To establish the importance of VAMP-8 in those 
cells we aimed to perform bone marrow transplantation as suggested by some studies in 
the literature, such as Wagner et al (Burger and Wagner 2003). Nevertheless, we did not 
have the mice at that time since we started the backcrossing to C57BL/6. At the same 
time, and based on numerous data in the literature, all these cell types (platelets, 
macrophages, and endothelial cells) found to be important in atherosclerosis. This finding 
will not change the conclusion of the importance of VAMP-8 in exacerbating 
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atherosclerotic plaque formation. The data of immunohistochemistry, proved the 
presence of VAMP-8 in the lesions of the aortic root.  
In conclusion, the data in this chapter demonstrated that VAMP-8 plays a role in 
atherosclerosis. However, more experimentation is needed to further characterize the role 
of VAMP-8 in atherosclerosis, such as the effect of VAMP-8 deletion on leukocytes 
recruitments and infiltrations in the lesion area, measuring the levels of cytokines and 
chemokines release since its been suggested to play a major role in inflammation and 
atherosclerosis (Sachais, Turrentine et al. 2007). It was recently shown that, the deletion 
of VAMP8 in mice inhibited the serum level of TNF-α and thus reduced the inflammation 
(Pushparaj, Tay et al. 2009). The reduction of VAMP-8 activity or expression might be 
used as a novel therapeutic target to ameliorate lesion development in atherosclerosis.  
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Table 3-1. Mouse Characteristics. ApoE-deficient mice (Apo-E-/-) mice (C57BL/6J) 
were from Jackson Laboratory and VAMP-8 deficient (V8-/-) mice (C57BL/6Jx129SvJ) 
were provided by Wanjin Hong (Institute of Molecular and Cellular Biology, Singapore). 
Littermates from F2 crosses were used to as the four groups in this study: 
ApoE+/+/VAMP-8-/-. (a control for secretion defect), ApoE-/-/VAMP-8+/+ (a control for 
atherosclerosis), ApoE+/+/VAMP-8+/+ (a wild type control), and ApoE-/-/VAMP-8-/- (the 
test group). Polymerase chain reaction (PCR) analysis was used to determine genotypes 
using DNA from the tail tip. Mice were fed normal chow diet and examined for 
atherosclerotic lesions at an average of 50 weeks of age.  
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Figure 3-1. En-Face Analysis of Aortic Arch. 
Representative aortic arches from the four study groups are shown in En-Face display. 
The lesions were determined using Image Pro software (Media Cybernetics). The entire 
aorta for each mouse was collected between subclavian and iliac branches then pinned on 
dark paper. The plaques are in white color.  
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Figure 3-2. Quantification of the Atherosclerotic Lesions in Aortic Arch.  
Lesion size in the aortic root was quantified by computer-assisted imaging. Closed circles 
(wild type), open circles (VAMP-8-/-), closed triangles (ApoE-/-), and open triangles 
(ApoE-/-/VAMP-8-/-), represent the values from each mouse, diamonds represent the 
mean, bars represent ±SEM, (P value=0.097) using one way anova. 
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Figure 3-3. Oil Red O Staining of the Aortic Root.  
Representative sections of the aortic root from the four study groups are shown.  The 
upper cardiac portion of the heart was embedded in OCT compound and sections (10 
mm) from comparable regions were taken for analysis. The sections were then stained 
with Oil Red O (stain the lesions) and hematoxylin (stain the cells) to examine the lesion 
size. 
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Figure 3-4. Quantification of Atherosclerotic Lesions in the Aortic Root.  
Lesion size was quantified by computer-assisted imaging. Closed circles (wild type), 
open circles (VAMP-8-/-), closed triangles (ApoE-/-), and open triangles (ApoE-/-/VAMP-
8-/-), represent the values from each mouse, diamonds represent the mean, bars represent 
±SEM, (P value=0.009) using one way anova 
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Figure 3-5. Measurements of Total Serum Cholesterol.  
Total serum cholesterol of individual mouse from the four study groups are shown (in 
mg/dl). Serum was separated from whole blood by centrifugation at 2000 rpm for 20 
minutes. Ten µL of the serum was used in the enzymatic reaction (Wako Chemicals) to 
measure the total cholesterol. There is no difference between the total cholesterol level of 
ApoE-/- and the double knock out. 
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Figure 3-6. Measurements of Glucose Level.  
The level of plasma glucose determined for mice in the four study groups is shown (in 
mg/dl). Plasma was separated from whole blood by centrifugation at 2000 rpm for 20 
minutes. Plasma glucose was measured using the enzymatic reaction and the intensity of 
the brown color was measured at 475nm.There is no difference between the glucose level 
of ApoE-/- and the double knock out. 
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Figure 3-7. VAMP-8 Expression in Endothelial Cells and Macrophages.  
The HUVEC cell extract was prepared by lysing the culture of HUVEC cells with PBS 
pH 7.4/1% Triton X-100. For macrophages, mice were euthanatized by cervical 
dislocation and the peritoneal macrophages were collected by washing the abdominal 
cavity with 0.9% Saline. The protein concentrations for HUVEC and macrophages were 
determined by Bicinchoninic acid (BCA) assay. 25 µg of HUVEC extract, macrophages 
and mouse platelet equivalents (5×107) were loaded to a 15% SDS-PAGE gel and 
analyzed by western blotting for the indicated proteins.  
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Figure 3-8: VAMP-8 is Present in Aortic Root. 
Immunostaining of VAMP-8 was performed using, anti-VAMP-8 rabbit polyclonal 
antibody, in atherosclerotic lesions of aortic root. A) Macrophage rat monoclonal 
antibody (1:1000) was used as a control. B) Negative control, no primary antibody. 
Different concentrations of anti-VAMP-8 antibody used C) 1:200, D) 1:500, E) 1:10,000. 
Images were captured using ImagePro software. 
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Chapter Four 
The Role of Munc18b in Platelet Secretion 
 
Introduction 
Cellular exocytosis is a complex process, mediated by the soluble NSF attachment 
protein receptors (SNAREs). There are two classes of SNAREs: the v-SNARE (on the 
vesicle membrane) and the t-SNARE (on the target/plasma membrane). The interaction 
between the v-SNARE and the t-SNARE forms a four-helix bundle that zips the two 
membrane bilayers together leading to membrane fusion and release of the granule 
content. The process of exocytosis through SNARE proteins is strictly regulated. One of 
the key regulators is the Sec1/Munc18 (SM) family protein (Sudhof and Rothman 2009). 
Munc18 proteins function is either in intracellular trafficking or regulation of exocytosis 
(Toonen and Verhage 2003). Munc18 proteins act as chaperone proteins, specific for 
syntaxin/t-SNARE, to regulate membrane fusion. Platelets express three SM isoforms: 
Munc18a, Munc18b, and Munc18c (Reed, Houng et al. 1999; Houng, Polgar et al. 2003; 
Schraw, Lemons et al. 2003). Munc18a and Munc18c have been demonstrated to play a 
role in platelet secretion. This observation was identified either by using specific peptide 
inhibitors Munc18a/Pep3, and Munc18c/Pep3 (Schraw, Lemons et al. 2003), or a 
monoclonal anti-Munc18c antibody and a peptide-based inhibitor that disrupted 
Munc18c-syntaxin-4 interactions (Houng, Polgar et al. 2003). Recent studies of patients 
with Familial Hemophagocytic Lymphohistocytosis type 5 (FHL5), suggested that 
Munc18b is important for platelet function (Sandrock, Nakamura et al. 2010). FHL5 is 
linked to a mutation in the Munc18b/STXBP2 gene. However, it is not yet clear which 
one of the SM isoforms is the most dominant in human platelets and plays a key role in 
exocytosis. In this chapter, the role of Munc18b in platelet exocytosis will be dissected 
using platelets from FHL5 patients and molecular biology techniques to determine the 
association of Munc18b with other SNAREs complex that mediate platelet exocytosis 
and thus its function.  
 
Results 
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Munc18b is the Most Abundant SM Isoform in Human Platelets  
Among the seven SM isoforms, platelets express Munc18a, Munc18b, and 
Munc18c (Schraw, Lemons et al. 2003). To determine the relative abundance of the three 
Munc18s, recombinant proteins from cDNA expression constructs were titrated and used 
to generate standard curve for quantification (Figure 4-1A). There were ~2.5±0.1 
ng/5x107 of Munc18a (~450 molecules per platelet, n=6), 56.1±3.71 ng/5x107 of 
Munc18b (~10,240 molecules per platelet, n=6) and 27.8±0.82 ng/5x107 of Munc18c 
(~5,070 molecules per platelet, n=6). The specificity of Munc18a, Munc18b, and 
Munc18c antibodies was demonstrated by comparing their immuno-reactivities to the 
recombinant Munc18s (Figure 4-1B). The cross-reactivity of anti-Munc18b rabbit 
monoclonal antibody with Munc18a may be due to the sequence homology between the 
two proteins.  From this analysis, Munc18b is 2-fold more abundant than Munc18c and 
25-fold more abundant than Munc18a. This indicates that Munc18b is the most abundant 
isoform of SM proteins in human platelets. 
 
Characterization of Munc18s and SNARE Proteins in FHL5 Platelets 
Work using inhibitory peptides or antibodies suggested a role for Munc18a and 
Munc18c in platelets (Houng, Polgar et al. 2003); (Reed, Houng et al. 1999; Schraw, 
Lemons et al. 2003). Munc18a had an effect on secretion from α-granules, while 
Munc18c affected the secretion from all three granules. Due to limited availability of 
some reagents, the exact role of Munc18b could not be detected at that time. FHL5 is 
linked to a defect in Munc18b/STXBP gene, and provides a unique opportunity to 
examine the role of Munc18b in platelet function. In Figure 4-2A and B, Munc18b was 
completely absent in platelets from the two biallelic patients, P1 and P2. The 
heterozygote, P3, showed a ~30% reduction. Munc18a increased in both biallelic 
samples, but this increase was not sufficient to compensate for the loss of Munc18b 
(Figure 4-2A). Munc18c was unchanged (Figure 4-2A and B). These data indicate that 
the mutations in the two biallelic patients (P1 and P2) cause the production of an unstable 
Munc18b protein, which was not detectible in platelets. The mutation in the heterozygous 
patient (P3) had less of an effect on Munc18b levels. 
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In the literature, the interaction between Munc18s and their cognate syntaxin has 
been controversial. While some studies showed that Munc18 binds the short N-terminus 
of syntaxin (Sudhof and Rothman 2009), others showed that it can bind syntaxin in the 
closed conformation where the Habc domain is folded back onto the H3 SNARE domain. 
However the most recent proposed interaction is the binding of Munc18a to the N-
terminus of syntaxin, which allows Munc18a binding to the SNARE complex. Often, loss 
of a Munc18 isoform precipitates loss of a syntaxin isoform and vice-versa.  Syntaxins 
are dependent on the chaperone function of Munc18s (Cirstea, Kutsche et al. 2010); In 
Munc18a/b double knockdown neurosecretory cells, the levels of syntaxin 1, syntaxin-2 
and syntaxin 3 were significantly reduced (Han et al. 2009). A comparable effect was 
seen when Munc18c was knocked out, there was a significant reduction of syntaxin-4 
expression (Houng, Polgar et al. 2003). In Figure 4-2A and B, the loss of Munc18b 
caused a striking decrease in syntaxin-11 with limited effects on syntaxin-4 (syntaxin-2, 
7, and SNAP-23 were unchanged in biallelic P1). Munc18a showed slightly greater 
enhancement, while VAMP-8, Munc13-4 (FHL3), and Rab27a were unaffected. 
Munc18b was decreased in the heterozygous patient P3, around 50% of the control, 
causing syntaxin-11 level to be decreased. Syntaxin, Munc13-4, VAMP-8, and Rab27a 
were unaffected in the heterozygous P3, however Munc18a was slightly decreased. These 
data indicate that Munc18b is a chaperone for syntaxin-11 in platelets, and is important to 
stabilize syntaxin-11 and may play a role in localizing it to the plasma membrane as 
suggested in Han et al. (Han et al. 2004). 
 
Thrombin-Stimulated Platelet Secretion is Defective in FHL5 Platelets 
Previous studies showed that peptide inhibition of Munc18a, and Munc18c had an 
effect on platelet secretion. Munc18a inhibition had an effect on secretion from α-
granules, while Munc18c inhibition affected the secretion from all three granules. Due to 
limited availability of some reagents, the exact role of Munc18b could not be detected at 
that time. To investigate the role of Munc18b in platelet function, we analyzed platelets 
from FHL5 patients lacking Munc18b\STXBP2 gene. This approach provides a unique 
system to dissect the role of Munc18b in platelet exocytosis. Dose response assays were 
performed to examine platelet secretion from the biallelic and heterozygous FHL5 
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patients (Figure 4-3A and B respectively). In figure 4-3A, different concentrations of 
thrombin were used to stimulate platelet secretions from dense granules, α-granules, and 
lysosome. The reactions were stopped after 1 minute using hirudin. In control platelets 
(dark circles Figure 4-3A), there was a dose dependent increase of secretion from dense 
granules and α-granules that was maximum at 0.5 U/mL thrombin. The maximal release 
of serotonin from dense granules was about 80% and of PF4 from α-granules was about 
60%. However, the maximum lysosomal release in the control platelets was maximal at 
0.3 U/mL thrombin. Platelets from the biallelic patient (P1) had a severe secretion defect 
from both dense granules and α-granules, despite using high thrombin concentrations 
(0.5 U/mL). β-Hexosaminidase release from lysosome was also affected compared to the 
control; however, this defect seems to be corrected when higher concentrations of 
thrombin were used. The biallelic patient (P2) showed a similar defect. The heterozygous 
FHL5 patient (P3) showed a partial secretion defect (Figure 4-3B). Serotonin release 
from dense granules and PF4 release from α-granules were partially attenuated compared 
to the control. Lysosome release was largely unaffected, showing similar percent of 
release as the control. 
 
ATP Release and the Exposure of Granule Membrane Proteins were Affected in 
FHL5 Platelets  
The previous experiment suggests that Munc18b is required for platelet cargo 
release was demonstrated. As an additional measure the release of ATP from dense 
granules was measured using luciferin/luciferase assay (Figure 4-4A and B). In Figure 4-
4A, a complete loss of Munc18b in the biallelic FHL5 patient (P1) (Figure 4-4A, grey 
line) resulted in a significant defect of ATP release from dense granules, compared to the 
control (Figure 4-4A, dark line). The ATP secretion defect was also observed in the 
heterozygous FHL5 patient (P3) (Figure 4-4B). The level of the ATP release from the 
biallelic FHL5 patient (P1) (Figure 4-4B, grey line) was around 50% less that the control 
(Figure 4-4B, black line) further confirming the role of Munc18b in platelet exocytosis.  
Activation of platelets not only releases the soluble cargo proteins as investigated 
above, but also leads to the exposure of membrane proteins. Thus we aim to investigate 
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the exposure of membrane receptors (P-Selectin and PAC-1) as an additional measure of 
α-granules release. Washed control and biallelic FHL5 patient  (P1) platelets were either 
used as resting (Figure 4-5A-B, grey line) or stimulated with 0.1 U/mL thrombin for 3 
minutes (Figure 4-5A-B, red color), and the reactions were stopped using 2 fold excess of 
hirudin. Flow cytometry was used for analysis. The phenotype was robust in the biallelic 
FHL5 patient (P1) upon platelets stimulation; the fluorescence intensity of P-Selectin 
expression (Figure 4-5A and C, grey bar) was around 60% less compared to the control. 
Similar results were observed in PAC-1 expression in the biallelic FHL5 patient (P1) 
Figure 4-5B and D, grey bar). From this we conclude that Munc18b is required for 
platelet secretion.  
 
Platelet Morphology is Normal in Platelets From FHL5 Platelets 
Platelet activation leads to cytoskeleton rearrangements that are important for 
platelet secretion. Since the lack of Munc18b has an effect on platelet secretion, it is 
possible that this defect is due to a defect in cytoskeleton rearrangements, where platelets 
undergo shape change without release of their granule content, so the granules will be 
centralized instead of fused to the plasma membrane. This observation was seen before 
(Ren 2008, Ren 2010).  To investigate this possibility, both resting and thrombin 
stimulated platelets from control and the biallelic FHL5 patient (P1) were examined by 
transmission electron microscopy (Figure 4-6). Resting platelets from control (Figure 4-
6A) and biallelic FHL5 patient (P1) (Figure 4-6B), showed normal discoid shape, with 
similar distribution of granules, microtubular network, mitochondria, and OCS. Control 
platelets stimulated with 0.1 U/mL thrombin, showed shape change with protruding 
filopodia, and lack of granule contents in the control (Figure 4-6C). This is the typical 
morphology of platelets after stimulation. Thrombin-stimulated, patient (P1) platelets 
showed shape-change, however the granules were centralized and with full cargo, 
indicating a defect in fusion of the granules to the plasma membrane and thus in the 
secretion of the granule contents. This data indicates that the lack of Munc18b did not 
affect platelets morphology and certainly is not required for platelets shape change and 
cytoskeleton rearrangements.  
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Munc18b Association with SNARE Proteins 
It is clear from the previous experiment (western blot data), that the lack of 
Munc18b from both the FHL5 biallelic patients (P1and P2) and from the heterozygous 
(P3) patient highly affected the level of syntaxin-11. These data indicate that Munc18b is 
a chaperone for syntaxin-11, and that the lack of one protein affects the stability of the 
other which in turn affects platelet exocytosis. Thus to investigate this further, the 
association of Munc18b protein with syntaxin-11 and other SNARE proteins was 
investigated. Resting and thrombin-stimulated platelets were subjected to 
immunoprecipitation using both anti-Munc18b and anti-syntaxin-11 antibodies, followed 
by western blot analysis to determine the association with SNARE proteins. In Figure 4-
7A, Munc18b was associated with syntaxin-11 in both resting and stimulated platelets 
lysates. There was no association between Munc18b and other syntaxins, indicating a 
specificity of the association of Munc18b to syntaxin-11. To characterize this association 
further, anti-syntaxin-11 rabbit polyclonal antibody was found to associate with Munc18b 
(Figure 4-7B). This data is consistent with the concept that each SM protein binds to its 
cognate syntaxins (Garcia, Gatti et al. 1994; Hata and Sudhof 1995; Reed, Houng et al. 
1999; Schraw, Lemons et al. 2003). Munc18b was associated with other SNARE 
proteins: Munc13-4, Rab-27a and SNAP-23, suggesting it plays a role in regulating 
SNARE complex and thus in platelet exocytosis. Using anti-syntaxin-11 rabbit 
polyclonal antibody, syntaxin-11 was found to associate with VAMP-8 and SNAP-23. 
These data suggest that Munc18b is a chaperone for syntaxin-11, and show an association 
between Munc18b and SNARE complex, which as we show earlier have an effect on 
platelet secretion. 
 
Discussion 
The work in this chapter shows that Munc18b is the major SM protein in platelets 
compared to the levels of other SM isoforms, Munc18a and Munc18c (Figure 4-1A and 
B). FHL5 patients lacking Munc18b gene was a perfect in vivo model to study the role of 
Munc18b in platelets exocytosis. Munc18b was completely deficient in biallelic FHL5 
patient (P1), while it was partially decreased in the heterozygous patients (P3). This 
decrease in Munc18b was associated with decrease level of syntaxin-11. These data are 
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consistent with the role of the SM protein Munc18 as syntaxin chaperone proteins 
(Garcia, Gatti et al. 1994; Reed, Houng et al. 1999; Misura, Scheller et al. 2000), and 
suggest that syntaxin-11 could be a required t-SNARE for Munc18b (Ye et al. 2012 
submitted). The relative importance of syntaxin-11 cannot be definitively established, but 
its level is clearly dependent on expression of Munc18b. Their levels were highly 
compromised and partially decreased in compared to the control.  
The secretion phenotype shown in Figures 4-3A and B clearly identified a 
significant role of Munc18b in platelet exocytosis. Thrombin-stimulated release from the 
biallelic FHL5 patient (P1) was extremely attenuated from granules and α-granules 
(Figure 4-3A), while lysosomal release was moderately affected. In the heterozygous 
(P3), the release from dense granules and α-granules was partially compromised. A 
similar conclusion was demonstrated in the defect of ATP release from the dense granule. 
This indicates that Munc18b might be a limiting component of the secretory machinery 
given the partial secretion defect noted in the heterozygous platelets. Our observation of 
the defect in P-Selectin and PAC-1 expression from α-granules, in biallelic FHL5 patient 
(P1) and the heterozygous patient (P3) suggests that the lack of Munc18b might affect 
platelet signaling and its subsequent events of secretion. This defect in platelet exocytosis 
was not related to platelet morphology or cytoskeleton rearrangements. The lack of 
Munc18b had no affect on platelets shape change indicating that signaling required for 
cytoskeleton rearrangements is still intact. Taken together, these data imply a significant 
role of Munc18b in platelet exocytosis. 
Despite the published results that showed a role of Munc18b in platelets secretion 
in FHL5 patient (Sandrock, Nakamura et al. 2010), the data was limited to only FACS 
analysis, without clarifying how Munc18b contributes to the regulation of SNAREs 
machinery in platelets. Our study, further characterizes the role of Munc18b in platelet 
secretion by investigating its association with SNARE proteins (Figure 4-5). Munc18b 
clearly interacted with syntaxin-11 and vice versa. In addition, there was an association 
between Munc18b and other SNARE proteins mediators such as, Munc13-4, Rab27a, and 
SNAP-23. These results suggest a role of Munc18b in regulation of SNARE machinery 
and thus platelet exocytosis. Previous studies revealed that Munc13-4 (FHL3) and Rab27 
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(GS2) are important for platelet exocytosis (Tolmachova, Abrink et al. 2007; Ren, 
Wimmer et al. 2010).  
In this chapter, we demonstrate that Munc18b is the dominant SM protein in 
platelets and that it is important in platelet exocytosis. We also show that Munc18b is a 
chaperone for the t-SNARE syntaxin-11, and the association between Munc18b and 
SNARE proteins. However, further work is needed to further characterize the importance 
of this interaction in SNARE proteins assembly and exocytosis. This work also suggests 
that platelet function assays may be useful diagnostic tools for FHL patients. 
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Figure 4-1. Munc18b is the Major Munc18 Isoform in Platelets and is Missing in 
Platelets from FHL5/STXBP2 Patients.  
A) Recombinant Munc18a, b, and c were used to generate a standard curve for 
quantification (using Enhanced Chemi-Fluorescence western blotting) of each Munc18 
isoforms in the indicated number of human platelets. Quantification of each isoform 
shows that ~2.5±0.1 ng/5x107 of Munc18a (~450 molecules per platelet, n=6), 56.1±3.71 
ng/5x107 of Munc18b (~10,240 molecules per platelet, n=6) and 27.8±0.82 ng/5x107 of 
Munc18c (~5,070 molecules per. B) Equal amounts of each Munc18 isoform were 
subjected to western blotting with the antibodies used in this study to evaluate their cross 
reactivity. (Data in panel A and some of the data in panel B, contributed by Dr. 
Qiangshen Ren) 
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Figure 4-2. Munc18b is Missing in Platelets from FHL5/STXBP2 Patients.   
A) Washed platelet extracts (1.0 - 2.0 x 107 platelets/lane) from control and FHL5 
patients were probed by western blotting, using SDS-PAGE, with the indicated 
antibodies and the ratio of patient to control levels of each protein were measured and 
graphed (B). 
A 
 
B 
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Figure 4-3. Platelets from FHL5/STXBP2 Patients Have a Secretion Defect.  
Platelet rich plasma (PRP) was generated by centrifugation and labeled with [3H]-
serotonin. After washing, platelets were stimulated with increasing concentrations of 
thrombin for 5 minutes and then release of [3H]-serotonin (Dense), PF4 (Alpha) and β-
hexosaminidase (Lysosomes) were measured as described (Chen, Lemons et al. 2000) (A 
and B). A) Show the release profiles for biallelic Patient 1 (open symbols) and a normal 
control (closed symbols). Patient 2 showed a similar profile. B) Show the release profiles 
for heterozygous Patient 3 (open symbols) and a normal control (closed symbols). 
Contributed by Drs. Qiangshen Ren and Shaojing Ye. 
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Figure 4-4. Platelets from FHL5/STXBP2 Patients Have a Defect in ATP release. 
Washed platelets, stimulated with thrombin-induced (0.1 U/mL) release of ATP from 
dense granules were measured in a lumi-aggregometer as described (Ren, Wimmer et al. 
2010) (A and B). The ATP release profile from a normal control (black line) and biallelic 
Patient 1 (A gray line) and the heterozygous Pateint 2 (B gray line) are presented.  Data 
contributed by Dr. Zubair Karim. 
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Figure 4-5. Platelets from FHL5/STXBP2 Patients Have a Defect in P-Selectin 
andPAC-1 Exposure.  
Thrombin stimulated washed platelets from control (gray line/filling), or biallelic Patient 
1 (black line/filling) were incubated with FITC-conjugated P-Selectin antibodies (A and 
C) for 1 minute at room temperature. The reactions were stopped with hirudin and data 
was analyzed by flow cytometry. A similar experiment was repeated (B and D) using 
PAC-1 antibody. Data contributed by Dr. Zubair Karim. 
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Figure 4-6. Platelets Ultrastructure is Normal in FHL5/STXBP2 Patient. 
Platelets were prepared as described in Chapter Two. Platelet concentration was adjusted 
to 2.5x108/mL and 0.7 mM CaCl2 was added. Platelets from control or biallelic Patient 1, 
were either in resting (A and B) or stimulated (C and D) with 0.1 U/mL of thrombin. 
Samples were then fixed and images were analyzed using transmission electron 
microscopy. Scale bars represent 0.5 µm. Data contributed by Dr. Zubair Karim 
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Figure 4-7. Munc18b Association with Syntaxin-11 and Other SNARE Proteins. 
Washed platelet extracts, resting or stimulated, were lysed with 2% n-Octyl-β-
glucopyranosidefor Munc18b immunoprecipitation (IP), or with Triton-X100 for 
syntaxin-11 IP, with protease inhibitor cocktail. The extracts were incubated either with 
anti-Munc18b rabbit polyclonal antibody (A), or with anti-syntaxin-11 rabbit polyclonal 
antibody (B), or IgG control (A and B), then cross linked with Protein A- Sepharose 
beads for 2 hours at 4oC. Association of Munc18b and syntaxin-11 with each other and 
with other SNARE proteins was detected by western blotting, as in panel A and B, 
respectively. 
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Chapter Five 
Ras Signaling in Platelets of Noonan Syndrome Patients 
Introduction 
Platelet activation is essential for hemostasis and thrombosis. Platelets sense the 
vascular damage and adhere to the exposed collagens. This binding to collagen and other 
agonists at the site triggers several signaling transduction events that lead to platelet 
activation, cytoskeleton rearrangements, and release of granule contents. Among the 
proteins that are thought to play a role in platelet function is the Ras GTPases 
superfamily. This chapter we will focus on Ras. Ras becomes activated by the conversion 
from GDP- to GTP-bound form.  This is mediated by the Guanine Exchange Factor 
(GEF) protein, SOS. SOS binds to the effector protein, GRB2. The SH2 domain of GRB2 
binds the phosphorylated tyrosine residues on tyrosine kinase receptors and that leads to 
the localization of SOS-GRB2 complex to the plasma membrane and activation of Ras 
(Buday and Downward 1993; Rozakis-Adcock, Fernley et al. 1993). Activated Ras 
initiates several downstream signaling cascades such as Ras/MAPK pathway; Raf, MEK, 
and ERK1-2. Platelet stimulation by collagen or thrombin leads to activation of MEK and 
ERK signaling pathways (Borsch-Haubold, Kramer et al. 1995). ERK is known to play a 
role in platelet function and integrin activation (Flevaris et al. 2009), and it was suggested 
to be downstream of Ras in human platelets (Rosado and Sage 2001; Li, Zhang et al. 
2006). Watson et al showed that Ras is activated in platelets in response to thrombin, and 
glycoprotein VI (GPVI) agonists (Tulasne, Bori et al. 2002). It was suggested that Ras 
might play a role in integrin activation (Shock, He et al. 1997). Despite these reports, 
little is known about the function of Ras in platelets.  
Noonan syndrome (NS) is a genetic defect in Ras/MAPK signaling pathways of 
PTPN11, K and N Ras, SOS, and Raf (Tartaglia, Martinelli et al. 2006; Zenker, Horn et 
al. 2007; Zenker, Lehmann et al. 2007; Tartaglia, Gelb et al. 2011). Thus it provides an in 
vivo tool to understand the role of Ras signaling in platelets. Platelets from NS patients 
with different mutations in Ras signaling pathway were investigated. Three of the four 
patients with mutations in K-Ras and PTPN11 showed a platelet aggregation defect. This 
study suggests several things: 1- NS serves as a model to study Ras signaling and its role 
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in platelet function, 2- Platelet function testing may be useful as a diagnostic approach to 
diagnose patients with NS.  
Results 
Patient Genotyping 
 Noonan syndrome (NS) is an autosomal genetic disorder that involves several 
proteins in the Ras/MAPK signaling pathway. These patients might present with bleeding 
problems that could be related to either a defect in coagulation pathway, such as 
deficiency in Factor XI or a defect in platelet function. There is insufficient data in the 
literature about platelets function in NS; thus, our goal is to understand the role of Ras 
signaling in those patients. Mutations in PTPN-11 are the most common, followed by 
SOS mutations. In addition, K-Ras, and N-Ras, Raf, MEK, and ERK are found to be 
mutated in NS patients. The purpose of this section is to characterize the function of Ras 
in patients with NS. Table 5-1, presents the characteristics of the four patients that were 
involved in our study. Patient 2 has a mutation in Raf1, patient 3 and 4 have a K-Ras 
mutation, while patient 5 has a PTPN11 mutation. The coagulation tests (PT and PTT) 
were normal (data was provided by Dr. Vlad Calin Radulescu, Pediatric Hematology 
Oncology University of Kentucky, KY, USA), and there were no overt bleeding 
abnormalities.  
 
Adjusting the Experimental Conditions 
  Only a few studies have examined the role of Ras in platelet function (Shock, He 
et al. 1997; Tulasne, Bori et al. 2002). Thus we aimed to study Ras activation in platelets 
from NS patients. The Ras-Effector domain pull-down assay technique was utilized as 
described in Chapter Two. Since we were dealing with a small quantity of patient blood 
(around 20-30 ml), we needed to standardize the conditions for both platelet function and 
Effector domain pull-down assay. Figure 5-1 shows the dose-dependent aggregation of 
platelets (Figure 5-1A) when stimulated with increasing concentrations of thrombin 
(0.02, 0.05, and 0.1) U/mL. The ATP release from dense granules (Figure 5-1B) was also 
dose-dependent. The Ras pull-down assay was performed using different concentrations 
of the recombinant protein Raf-Ras Binding Domain (Ras-RBD): 10, 20, 50, 100, 200, 
and 300 µg (Figure 5-2A and B) to determine the appropriate concentration for binding of 
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the recombinant protein to the Ras-GTP in platelets. As indicated in Figure 5-2A, the 
binding was accomplished at concentrations between 100-300 µg of Raf-RBD 
recombinant protein, and the 200 µg of protein was chosen for the experiments.  Fresh 
human platelets, stimulated with 0.1 U/mL thrombin were subjected to Ras Effector 
domain pull-down assay and immune blotting (Figure 5-2). Ras-GTP was found in 
resting but its levels increased in stimulated platelets, with a peak between 30 and 60 
seconds (Figure 5-2B). Total platelet input used as a control (Figure 5-2C) showed total 
Ras protein.  
 
Characterization of Platelet Function in Noonan Syndrome (NS) Patients 
 Bleeding abnormalities have been reported in the literature as one of the most 
serious, yet under-studied complications associated with NS. The bleeding problems 
could be due to a defect in coagulation factors or a defect in platelet function. However 
the nature of the defect in platelets is not yet known. Noonan syndrome patients having 
defects in the Ras/MAPK pathway provide the ideal model to study Ras activation in 
platelets and to understand the cause of platelets defect in these patients.  
 Five patients were involved in this study.  The first patient was excluded from 
interpretation due to insufficient amount of platelets and some technical difficulties. 
When stimulated with different concentrations of thrombin, platelets from patient 2 
(RAF1 mutation) (Figure 5-3B), showed normal aggregation traces compared to the 
control (Figure 5-3A). In Figure 5-3C, the percentage of aggregation for patient 2 and the 
control is illustrated. There was a defect in aggregation in platelets from patient 3 and 
patient 4 (daughter and mother with heterozygous K-Ras mutation) (Figure 5-4). There 
was a defect in aggregation compared to the control (Figure 5-4A) despite increasing the 
concentrations of thrombin (Figure 5-4B and C) in both patient 3 and patient 4. Figure 5-
4D shows the percentage of aggregation for the control, patient 3 and patient 4. Patient 5 
(mutation in PTPN11) showed an aggregation defect (Figure 5-5A, B, C, and D), and 
ATP release defect (Figure 5-5E, F, G, and H). The percentage of aggregation was 
plotted (Figure 5-5J). In patient 5 (Figure 5-5D), despite increasing the concentration of 
thrombin (0.2 U/mL), the control had a lower percentage of aggregation (50%). Platelets 
could have lost activity, which is expected when platelets are kept for a long time at room 
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temperature. A fresher preparation of platelets will be required to rule out this possibility. 
However, the phenotype of platelet dysfunction is still obvious in this patient.  
Discussion 
 The defect in Noonan Syndrome (NS) is associated with mutation in Ras/MAPK 
gene family (Turner 2011). There are several publications about the genetic and the 
clinical abnormalities in NS; however, the hematological abnormalities are poorly studied 
in the literature.  There is a 15 years gap between the last review of bleeding disorders in 
Noonan Syndrome, by Singer et al (Singer, Hurst et al. 1997) and the review recently 
published by Briggs et al (Briggs et al. 2012). There are different causes of bleeding 
abnormalities in patients with NS, such as: defect in coagulation factors, von Willebrand 
disease, thrombocytopenia, and platelets dysfunction. Furthermore, Ras function in 
platelets has been poorly documented; only a few reports have been published (Shock, He 
et al. 1997; Tulasne, Bori et al. 2002). Thus, the focus of this chapter is to understand the 
role of Ras in platelets function using NS as an model system.  
  Patient’s chosen for this study, fit the genetic and the clinical criteria of NS (work 
was performed by (Dr. Vlad Calin Radulescu, Pediatric Hematology Oncology 
University of Kentucky, KY, USA). The biochemical analysis using platelet aggregation 
and secretion were performed in our lab. It is important to notice that, despite the fact that 
the patients involved in this study have no overt bleeding diathesis; this does not exclude 
platelet dysfunction. The conditions of isolating platelets from a small amount of blood, 
performing platelet function tests were established. Patient 2 had a mutation in Raf1, 
showed no defect in platelets aggregation. One possibility could be because not all the 
mutations in NS are associated with platelet dysfunction; the incidence of bleeding 
abnormalities is between 50-89% (Briggs and Dickerman 2012). However defects in 
platelets aggregation and secretion were observed in patients with K-Ras (patient 3 and 4) 
and PTPN11 (patient 5) mutations. In conclusions, this study showed that Ras signaling 
pathway is important for platelet function, however extensive investigation is required to 
understand the mechanism causing this defect. For instance, we need to determine if the 
level of Ras-GTP is affected in those patients by performing Ras pull down assay. In 
addition, the ERK phosphorylation, downstream of Ras, could also be affected as well. 
ERK is known to play a role in platelets secretion and integrin activation. Flevaris et al. 
82 
 
 
showed that ERK inhibitors affected platelet secretion (from both dense granules and α-
granules), aggregation, and the integrin mediated clot retraction (Flevaris, Li et al. 2009). 
Further analysis that involves detection of downstream signaling such as ERK 
phosphorylation is required. NS provides an ideal model to answer all these questions 
related to Ras pathway in platelets function.  
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Table 5-1. Characteristics of Noonan Syndrome (NS) Patients. 
 Presented in this table are the conditions of NS patients used for the study: the age, sex 
and the genotype of the mutations in NS patients.  
* Patient 4 is the mother of Patient 3. The genotype record is not yet identified. 
SUBJECT Patient 2 Patient 3 Patient 4 Patient 5 
Age (years) 34 3 37 2 
Sex F F F F 
Genetic Mutation RAF 1 P261R 
K-Ras 
F156V 
*Daughter 
with Noonan 
has  K-Ras 
PTPN11 
D61N 
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Figure 5-1. Characteristics of Platelets Aggregation and Secretion in Healthy 
Controls. 
Platelets function studies including aggregation and secretion are presented. Washed 
human platelets from a healthy control were stimulated with different concentrations of 
thrombin (A and B) and incubated at 37oC with constant stirring. Platelet aggregation (A) 
and ATP release (B) were measured with constant stirring.  
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Figure 5-2. Characteristics of Platelets Ras Pull Down Assay. 
Washed human platelets (4 × 108/mL) were incubated 0.1 U/mL thrombin with stirring at 
37°C (A-C). Platelets were incubated with different concentrations of Ras recombinant 
proteins (Raf-RBD), lysed at the indicated time points and the supernatants were used to 
pull down the Ras-GTP (A), as described in Chapter Two. The detection of Ras was 
accomplished by western blot, using anti-Ras antibody. B) Western blot of Ras-GTP pull 
down in human platelets, stimulated with 0.1 U/mL thrombin, and incubated with 200 µg 
of recombinant protein Raf-RBD at the designated time points. C) Ras-GTP in platelets 
input. 
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Figure 5-3. Noonan Syndrome Patient with RAF1 Mutation has a Normal Platelet 
Function. 
Washed human platelets from a healthy control (A) and patient 2 (B) were stimulated 
with the designated concentrations of thrombin (A and B) and incubated at 37oC with 
constant stirring. Platelet aggregation was measured. C) Scatter graph present the 
percentage of aggregation for both the control (A, diamond shape) and patient 2 (B, circle 
shape). 
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Figure 5-4. Noonan Syndrome Patients with K-Ras Mutation have Defect in Platelet 
Function. 
Washed human platelets from a healthy control (A), patient 3 (B), and patient 4 (C) were 
stimulated with the designated concentrations of thrombin and incubated at 37oC with 
constant stirring. Platelets traces are presented (A-C). D) Scatter graph present the 
percentage of aggregation for the control (diamond shape) and patient 3 (circle shape), 
and patient 4 (triangle shape). 
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Figure 5-5. Noonan Syndrome Patients with PTPN11 Mutation have Defect in 
Platelet Function. 
Washed human platelets from a healthy control (red line) and patient 5 (blue line) were 
stimulated with the designated concentrations of thrombin and incubated at 37oC with 
constant stirring. Platelets aggregation traces (A-D, control: red line, patient5: blue line), 
and ATP release (E-H, control: black line, patient5: blue line). J) Scatter graph present 
the percentage of aggregation for the control (diamond shape) and patient 5 (circle 
shape). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Copyright © Rania Al Hawas 2012 
90 
 
 
Chapter Six 
Conclusions and Future Directions 
The data in this thesis represents a body of work that focuses on various, yet 
related, aspects of platelet secretion. Platelets, the small cellular fragments, circulating in 
the blood stream, respond to various stimuli, such as vascular injury, wound healing, and 
inflammation; in a very complex and strictly regulated manner. Platelets provide a unique 
system to study the regulation of SNARE machinery in exocytosis. Thus we asked 
several questions related to the regulation of platelet secretion and how it influences 
pathological conditions. We wanted to know 1) if the v-SNARE, VAMP-8, plays a role 
in atherosclerosis, 2) how the process of platelet exocytosis is regulated by Munc18b, and 
3) what is role of the small GTPase, Ras, in platelets. In vivo systems, mice and humans, 
provide the novel tools to answer our questions. This chapter provides a summary of the 
work and future implications. 
 
Platelet Secretion and Atherosclerosis 
This section of the thesis is related to the first question; what is the role of 
VAMP-8-mediated secretion in atherosclerosis. In the literature, there has been a focus 
on the role of platelets in the later stages of atherosclerosis, when the plaque has ruptured. 
However, recent data suggest that platelets might participate in early stages of 
atherosclerosis as an inflammatory cell in the vessel wall. Sachais et al. showed evidence 
of PF4 deposition, secreted from α-granules, in the plaques of patients with coronary 
heart disease (Sachais, Higazi et al. 2004). Additionally, it was shown that PF4 promotes 
atherosclerotic lesion development in ApoE-/- mice and its deletion had a protective effect 
(Sachais, Turrentine et al. 2007). These data indicate that platelet secretion is important 
for atherosclerosis. As mentioned earlier, the process of platelet exocytosis is complex 
and strictly regulated. The field of platelet secretion was controversial regarding which 
VAMP is important for platelet exocytosis (Flaumenhaft, Croce et al. 1999; Polgar, 
Chung et al. 2002; Schraw, Rutledge et al. 2003).  Our group identified VAMP-8 as the 
primary v-SNARE that is required for platelet secretion from the three granules (Ren, 
Barber et al. 2007). They also showed that VAMP-8 is not only important for platelet 
secretion but also in thrombus formation and stability (Graham, Ren et al. 2009).   
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Taking these data together, we aimed to determine if VAMP-8-mediated events 
are important for atherosclerosis. Our results indicated that the deletion of VAMP-8 
decreased the lesion size in aged ApoE-/- mice, in aortic root and arch. The effect was 
more prominent in the aortic root. The fact that we saw a significant difference in one 
area of the aorta but not the other is intriguing.  Differential plaque deposition has been 
noted previously in the literature (Goel et al. 2008). However, some causes could be due 
to: 1) the variations in murine studies (each mouse respond differently to the disease 
though they are congenic), 2) the mouse number, if it was increased in the ApoE-/-
/VAMP-8-/- group perhaps statistical significance could have been reached, or 3) the 
interaction of local hemodynamic forces with vessel wall (Frangos et al. 1999).  Further 
work is needed to understand the link between the intracellular stimuli and hemodynamic 
forces.  
Our data showed a strong phenotype. This work has several potential future 
implications; for the first time, it links VAMP-8-mediated secretion events to the 
inflammatory process of atherosclerosis. Another study suggested a correlation between 
an SNP in the 3’ untranslated region of the VAMP-8 gene and early onset of myocardial 
infarction (MI) (Shiffman et al. 2006). Complicating further interpretation is the fact that 
VAMP-8 is expressed in several cells in the body.  It will be interesting to understand the 
role of VAMP-8 in other cell types to determine how these events contribute to the risk of 
cardiovascular diseases. In addition, a platelet-lineage-specific deletion of VAMP-8 will 
provide a unique tool to study several inflammatory processes in which platelets might 
play a role, such as sepsis (Yaguchi et al. 2004) and rheumatoid arthritis (Wang et al. 
2007). In addition, this model gives an opportunity to uncover the role of platelet 
secretion in other pathological conditions such as cancer. Platelets contribution to cancer 
progression has been suggested in the literature (Varki et al. 2001; Borsig 2008) 
Understanding the role of VAMP-8 in secretion and its effect on various 
pathological conditions such as atherosclerosis is very important for pharmaceutical 
interventions: 1) Platelet secretion is important in atherosclerosis, thus suggesting anti-
platelet therapy might be valuable to individuals with risk of cardiovascular disease. 2) 
VAMP-8 is important in secretion events; thus it is a unique molecular target for 
pharmaceutical interventions. From a bird’s eye view, targeting VAMP-8 might be 
92 
 
 
useful, but anti-VAMP-8 therapeutics could have several side effects. Deletion of 
VAMP-8 in mice does cause abnormalities in the pancreas and the salivary and lacrimal 
glands (Wang et al. 2007).  It can also cause splenomegaly (Wang, Ng et al. 2004). Thus 
targeting the interaction between the complex involved in platelet secretion (VAMP-8, 
Syntaxin-11 and SNAP-23) might be a more specific approach. This interaction is 
specific for SNARE regulated platelets exocytosis. Evidence presented in this thesis 
suggests that VAMP-8 might play a role in inflammation. The deletion of VAMP-8 in 
ApoE-/- mice lessen the plaque compared to the control group, the reason could be due to 
the effect of VAMP-8 on the secretion of inflammatory molecules from platelets, thus 
targeting VAMP-8 might lead to less inflammation in the patients with high risk of 
cardiovascular diseases and thus reduces the risk of plaque development and thrombosis. 
For instance, small-molecule-targeted therapy might lead to inactivation of VAMP-8 
hindering it from binding the t-SNARE and driving the fusion and secretion. However 
that should not lead to complete inhibition of secretion. In addition, anti-platelet therapy 
might be useful not only as anti-thrombotic but also as anti-inflammatory target since 
cytokines released by platelets (e.g. PF4) are known to present in atherosclerotic plaques 
in patients with cardiovascular diseases and corresponds to the severity of the disease. 
From the diagnostic point of view, measuring the levels of inflammatory molecules 
released by platelets (e.g. CD40L and P-Selectin) might be useful for early diagnosis and 
evaluating the severity of the disease. 4) Platelet function tests can be used to evaluate the 
efficacy of anti-platelet therapy (Brass 2010) such as patients on anti-platelet therapy who 
could present with a second episode of myocardial infarction; or it can be used as a low-
cost diagnostic tool for patients at high risk of cardiovascular diseases compared to 
magnetic resonance imaging scans. For example aggregation studies and flow cytometry 
(measuring P-Selectin exposure and PAC-1 binding) could indicate platelets 
hyperactivity but can not exclude the risk of thrombosis in patients with normal platelet 
function, thus this test will be useful if combined with medical history of the patient.  
Taken together the above conclusions, preventive measures and future directions 
might be useful in advancing the field of cardiovascular diseases.  
Munc18b in Platelet Secretion and its association to Familial Hemophagocytic 
Lymphocytosis type 5 (FHL5) 
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The Sec1/Munc18 family proteins are known to play a regulatory role in SNARE 
secretion machinery by acting as a chaperone for syntaxins. Among the three isoforms 
expressed in platelets, data from our laboratory and others show that Munc18a, and 
Munc18c, could be important for platelet secretion. (Reed, Houng et al. 1999; Houng, 
Polgar et al. 2003; Schraw, Lemons et al. 2003). The role of Munc18b could not be 
defined at the time of those studies due to limited reagents. FHL5 patients, with defects in 
the Munc18b gene, offer an opportunity to study the role of Munc18b in platelet 
exocytosis. Our data show that Munc18b is the most abundant isoform and that it might 
be a limiting factor in platelet secretion. There was a complete loss of Munc18b protein 
in the two-biallelic patients and a partial decrease in the heterozygous patient. The gene 
mutations in these patients might lead to instability of the Munc18b protein that leads to 
its degradation as suggested by the study of FHL5 in NK cells (Cote et al. 2009). Platelet 
secretion defect was prominent and suggests that Munc18b might be the primary Munc 
family member in platelets.  The reasoning behind this is the secretion phenotype. 
Platelet secretion was severely affected from dense granules (serotonin and ADP/ATP) 
and α–granules (PF-4 and P-Selectin exposure) in the biallelic patients and partially so in 
the heterozygous patient.  This would indicate that neither Munc18a nor Munc18c 
compensate for the loss of Munc18b and that Munc18b could be a limiting factor in 
platelet secretion. Similar phenotype was seen by our group in heterozygous Munc13dJinx 
mice with reduced level of Munc13-4 (Ren, Wimmer et al. 2010). There was no 
difference in platelet morphology between the FHL5 patients and the control. This 
suggests that platelet biogenesis and cytoskeleton rearrangements were not affected by 
the loss of Munc18b and the present phenotype is due to the effect that the loss of 
Munc18b has on membrane fusion and thus the secretion. Hennies group and de Saint 
Basile group suggested that Munc18b/syntaxin-11 is a functional pair in NK cells (zur 
Stadt et al. 2009) (Cote, Menager et al. 2009). The loss of Munc18b caused a decrease in 
syntaxin-11 levels in NK cells from patients with FHL5. This is consistent with our 
results. The loss of Munc18b caused a decrease in syntaxin-11 levels in platelets from 
FHL5 patients and suggests that it is a functionally relevant pair. To further confirm this 
observation, the immunoprecipitation experiment showed that Munc18b and syntaxin-11 
interact in a complex. Analysis of platelets from FHL-4 patient with a defect in syntaxin-
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11 sowed similar phenotype seen in FHL-5 platelets (Ye et al. 2012 in revision). 
Munc18b not only found associated with syntaxin-11, but also with other SNARE 
machinery (VAMP-8 and SNAP-23) and its regulators (Munc13-4 and Rab-27a). These 
data together suggest a key function of Munc18b in platelet exocytosis. Thus it is 
important to further investigate these interactions and identify the proteins that Munc18b 
interacts with in the secretory pathway (Figure 6-1).  
The experiments describing the FHL5 platelets in this thesis were more definitive 
and suffered from fewer caveats than did the previous approaches for analyzing the role 
of Munc18’s in platelet secretion. For instance, the previous methods relied on inhibitory 
peptides (Munc18a/Pep3 and Munc18c/Pep3 peptide) and antibodies (Munc18a/b 
polyclonal antibody) that inhibit platelet secretion from permeabilized platelets (Schraw, 
Lemons et al. 2003). In addition, previous work with Munc18c+/- mice showed no platelet 
secretion defect (Schraw, Crawford et al. 2004). In permeabilized platelets, the use of 
monoclonal anti-Munc18c antibody and a peptide-based inhibitor affected the interaction 
between Munc18c and syntaxin-4 and enhanced platelet secretion (Reed, Houng et al. 
1999; Houng, Polgar et al. 2003). These results are in agreements with one of the closed 
confirmation hypothesis, where Munc18s bind to syntaxins in closed confirmation 
preventing them from interacting with SNARE complex, thus function as negative 
regulators for syntaxins and have an inhibitory effect on secretion. However, the results 
presented here and previous work by our lab (Schraw, Lemons et al. 2003) is in better 
agreement with the recent hypothesis that Munc18s remain associated with SNARE 
proteins (syntaxin and SNAP-23) throughout the secretion process thus function as a 
positive regulator for membrane fusion (Carr et al. 2010). In addition recent work from 
our lab showed that syntaxin-4, the cognate t-SNARE for Munc18c, has no role in 
platelet secretion (Ye et al. 2012 submitted). Thus Munc18b results in this thesis show 
more definitive role among the Munc18 isoforms in platelets secretion. 
The work presented here shows that Munc18b is the cognate Munc for syntaxin-
11 and that a decrease in Munc18b leads to a loss of syntaxin-11.  Munc18b not only 
binds to syntaxin-11 but also forms a complex with SNAP-23. This provided more 
evidence of the role that Munc18b plays in regulating SNARE machinery. However, 
further molecular work is required to understand the nature of the association of other 
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SNAREs proteins such as Munc13-4 and Rab27a, and its importance in regulating 
SNARE machinery. Figure 6-1 summarizes the conclusions of this part.  
FHL is a life-threatening disease, caused by uncontrolled and hyperactivation of 
the NK cells and T-cells, which lead to ineffective immune response that might lead to 
death if not treated. Clinical signs and symptoms involve fever that might associate with 
upper respiratory tract infection, hepatosplenomegaly, pancytopenia, coagulopathy, 
anemia, hypertriglyceridemia, and neurological abnormalities such as seizures(Janka 
2007). The treatment for FHL is immunosuppressive drugs followed by stem cell 
transplantation (Baker et al. 1997).  
Despite the clinical symptoms and the laboratory measures that have been created 
to aid the diagnosis, FHL5 still could be overlooked. Some of the reasons are that the 
symptoms are very similar to symptoms from normal infection, the clinical examination 
of hepatosplenomegaly could be poorly performed, and the prolonged antibiotic 
treatment might even further delay the diagnosis. The lipid profile is not a routine test. 
Some of the symptoms, such as fever might disappear (Janka 2007). These diagnostic 
measures are still not completely efficient and it is still difficult to diagnose unless 
genetic testing is performed, but it is costly. Therefore the presented data suggest a new 
diagnostic approach. Using platelet function test might lead to an early diagnosis and 
improve the survival rate of the patients as suggested recently by Pagel and et al. (Pagel 
et al. 2012).  
Taken together, these data provide several important considerations. 1) FHL 
provides a unique model to study other regulatory proteins in platelets secretion. The data 
showed that the defect in Munc18b affected secretion from the granule content. Further 
analysis of Munc18 association with SNAREs machinery (Munc13-4 and Rab27a) and 
how it regulates platelet secretion is required. Platelet as a secretory cell provides a 
unique system to study the regulation of SNAREs machinery. The outcomes of this study 
will assist in understanding the role of Munc18b in other secretory cells in the body. 2) 
As mentioned earlier, the diagnosis of FHL5 cannot rely only on the clinical symptoms of 
fever and fatigue, which are common symptoms of cold and can be misleading, unless 
genetic test is performed to assess the diagnosis. However, the platelet secretion defect, 
observed in FHL5 patients, raises the possibility that platelet function assays can be 
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advancement in the diagnosis of FHL. For instance, FACS analysis of P-Selectin 
exposure in platelets is considered to be a quick and efficient way to assist the diagnosis 
before the expensive genetic tests performed. The outcomes of these studies will provide 
the field with answers that facilitate understanding of the regulation of SNAREs 
machinery in other systems, such as secretion from natural killer (NK) cells, and improve 
the diagnostic methods for FHL patients. 
 
Ras GTPase in Platelets and Noonan Syndrome (NS) 
The last of this thesis is related to the role of Ras GTPase in platelet secretion. In 
platelets, the roles of other members of Ras and Rho GTPases have been tied to the 
control of cytoskeletal remodeling and integrin activation. These events are important for 
platelet function: adhesion, aggregation, and clot remodeling (Crittenden et al. 2004; 
Chrzanowska-Wodnicka, Smyth et al. 2005; McCarty, Larson et al. 2005; Akbar, Kim et 
al. 2007; Cifuni et al. 2008; Varga-Szabo, Pleines et al. 2008). However, very little is 
known about the role of Ras in platelets. Parise et al. showed that Ras is present in 
platelets and its GTP level increase upon platelets stimulation (Shock, He et al. 1997). 
Watson et al. showed that Ras is activated in platelets in response to thrombin (Tulasne, 
Bori et al. 2002). However it is not clear yet how Ras is activated in platelets and how 
this activation affects platelet function. 
Noonan syndrome is a common inherited disorder, associated with various 
clinical features, such as reduced growth, distinctive facial dysmorphism and 
hypertrophic cardiomyopathy (Noonan 1994). There is a high incidence of bleeding 
disorders in patients with NS (Briggs and Dickerman 2012). Patrick et al. made a 
recommendation to the clinicians to consider the diagnosis in patients with any bleeding 
disorder associated with congenital heart disease or short stature. In addition she 
recommended hematological tests to be performed, such as blood count and coagulation 
studies for all patients in general, and to investigate hemostasis further in patients with 
bleeding or bruising (Patrick et al. 2010). Platelet function tests such as aggregation have 
been used previously to investigate the function of platelets in NS patients; nevertheless 
in general platelet function in NS was poorly studied in the literature (Flick et al. 1991; 
Singer, Hurst et al. 1997; Briggs and Dickerman 2012). Unlike FHL patient who have a 
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clear platelet secretion defect, platelet secretion defect is common but not in all the 
population of NS, though we have seen it in the patient with K-Ras mutation. 
As mentioned above, Noonan Syndrome mutations are linked to the Ras/MAPK 
pathway, and bleeding problems. Therefore it is of a great benefit to use platelets from 
NS patients in order to dissect Ras activation and how it might influence platelet 
function. Noonan syndrome patients with different kinds of mutations in Ras/MAPK 
were included in a study to analyze their platelet function and investigate if there is a 
relation between the phenotype of platelet function and the genetic mutations in 
Ras/MAPK signaling pathway. The results showed that certain mutations in Ras/MAPK 
pathway, such as K-Ras mutation in the mother and the daughter, there was a defect in 
platelet aggregation despite the increasing concentration of thrombin. Similar phenotype 
was observed in platelets from the patient with PTPN11 mutation. Our data highlighted 
the fact of the importance of Ras in platelets aggregation and ATP release, and that a 
defect in Ras signaling might causes a defect in platelet function. There are still questions 
to be answered; how Ras activation affects platelet function and why it is important. 
There is a possibility that Ras might play a role in integrin activation. Platelet stimulation 
with agonist lead to activation of PLC followed by IP3 and an increase in cytoplasmic 
Ca2+ and induces inside-out signaling of integrin and subsequently platelet aggregation 
(Rink et al. 1982; Lian et al. 2005; Offermanns 2006). Activation of Ras could be 
upstream of PLC. It will be interesting to measure the Ca2+ mobilization in patients with 
mutation in Ras. In addition, it is also important to make sure that Ras is inactive in these 
patients by doing pull down assay as explained previously in Chapter Two. Another 
possibility of Ras function in platelets is that Ras could play a role in platelet 
cytoskeleton rearrangements similar to Rho GTPase.  
This study has several potentials; understanding platelet biology and the signaling 
events that influence platelet activation, aggregation, and secretion is required to maintain 
hemostasis and prevent bleeding. NS is a model to study defect in Ras signaling in 
platelets and other cells. In addition, understanding the importance of Ras in platelet 
function might be a useful therapeutic target for inhibiting platelet function in several 
diseases.  
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Over all the work in this thesis provides an insight about the molecular 
mechanism of platelet exocytosis and its role in physiological and pathological 
conditions. Understanding platelet biology and the process of secretion will have a great 
impact on the science field, not only for detection of new therapeutic targets but also to 
appreciate platelet as a unique system to study exocytosis and SNARE proteins.  In 
addition to considering platelet function assays as a quick and efficient diagnostic tool in 
genetic disorders that involve platelet secretion defect. 
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Figure 6-1: Summary of the Role of Munc18b in Platelet Secretory Pathway. 
Membrane fusion occurs in several steps. Munc18b (red) interacts with the t-SNARE 
(syntaxin-11 (blue) and SNAP-23 (green)) and the v-SNARE VAMP-8 (pink) to promote 
membrane fusion and secretion of the granule content.  Munc18b might also play an early 
role in regulating the secretion by it is association with other regulators in the secretory 
pathway such as Rab-27a (yellow) and Munc13-4 (brown). Further work is needed to 
further identify the interaction with other proteins upstream of the fusion step.  
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LIST OF ABBREVIATIONS 
 
5-HT Serotonin (s-hydroxytryptamine) 
ADP Adenosine di-phosphate 
ALL Acute lymphocytic leukemia 
AP Alkaline phosphatase 
Arf ADP-ribosylation factor 
ATP Adenosine tri-phosphate 
BCA Bicinchoninic acid  
β-TG β- Thromboglobulin 
DAG Diacylglycerol 
DMS Demarcation membrane system 
ECF Enhanced chemi-fluorescence 
ECM Extra cellular matrix 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immuno sorbent assay  
FACS Fluorescent-activated cell sorting 
FHL2 Familial hemophagocytic lymphohistiocytosis type 2 
FHL3 Familial hemophagocytic lymphohistiocytosis type 3 
FHL4 Familial hemophagocytic lymphohistiocytosis type 4 
FHL5 Familial hemophagocytic lymphohistiocytosis type 5 
FITC Fluorescein isothiocyanate 
FPLC Fast protein liquid chromatography 
GAP  GTPase activating protein 
GDP Guanosine di-phosphate 
GEF Guanine nucleotide exchange factor 
GPVI Glycoprotein VI 
GST Glutathione S-transferase 
GTP  Guanosine tri-phosphate 
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HUVEC Human umbilical vein endothelial cell 
IL-1β Interleukin-1β 
ICAM Intercellular adhesion molecule 
i.p. Intraperitoneal injection 
IP Immunoprecipitation 
IP3 Inositol tri-phosphate 
PI-4,5-P2 Phosphatidylinositol 4,5-bisphosphate  
IPTG Isopropyl-beta-D-thiogalactopyranoside 
LAMP Lysosomal-associated membrane protein 
LDCV Large dense-core vesicle  
LDL Low density lipoprotein 
LIMP Integral membrane protein 
MCP-1 Monocyte chemotactic protein-1 
MI Myocardial infraction 
MMP-9 Matrix metallopeptidase-9 
NK Natural killer 
NS Noonan syndrome 
NSF N-ethylmaleimide-sensitive factor 
OCS Open canalicular system 
PAGE Polyacrylamide gel electrophoresis 
PAI-1 Plasmingoen activator inhibitor-1 
PAR Protease-activated receptor 
PF4 Platelet factor 4 
PGI2 Prostaglandin I2 
PKC Protein kinase C 
PLC Phospholipase C 
PRP Platelet-rich plasma 
RIAM Rap1GTP-interacting adapter molecule 
SNARE Soluble N-ethylmaleimide-sensitive factor activating protein receptor 
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SNAP Synaptosome-associated protein  
SNP Single nucleotide polymorphism 
TNF-α Tumor necrosis factor-α  
TGF-β Transforming growth factor-β 
unc Uncoordinated mutants 
VAMP Secretory vesicle-associated membrane proteins 
VCAM Vascular cell adhesion molecule 
vWF von Willebrand factor 
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